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ABSTRACT

The glomerular basement membrane (GBM) of the kidney is highly specialized
and required for filtration of waste products from the bloodstream. One of the major
structural and functional units of the GBM is a network composed of type IV collagen
heterotrimers, or protomers. Early in development of the human and dog, an isoform
switch occurs, and the α1α1α2 (IV) network found in the nascent GBM is replaced with
α3α4α5 (IV) protomers. Mutations in any of the genes encoding proteins found in the
mature GBM network may prevent protomer formation and cause a progressive disorder
leading to end stage renal failure (ESRD). In the human, the disease is known as Alport
syndrome (AS) and is characterized by proteinuria, hematuria, and in half of affected
patients, deficits in hearing. The GBM undergoes characteristic ultrastructural changes,
and immunostaining of renal samples reveals a loss of α3 (IV) and α5 (IV) proteins with
a corresponding increase in α1 (IV) chains. Hereditary nephropathy (HN) is the canine
counterpart of AS and has been reported in different breeds. Affected dogs display
clinicopathological signs identical to those described in AS patients, with the exception
of hearing loss. There were two major objectives for this project. The first objective was
to amplify and sequence a region previously lacking coverage on CFA25 between the
genes encoding the α3 (IV) and α4 (IV) chains. This was necessary in order to span gap
regions in the canine reference genome. The second objective was to identify the
mutation causative for HN in a breed not previously reported to present with the disease.
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CHAPTER ONE
INTRODUCTION

The Dog as a Model
The domestic dog, Canis lupus familiaris, is a remarkable model for genetic
studies. More than 400 breeds of dog exist, carefully developed and selected for specific
morphological and behavioral characteristics that define individual breeds. Depending on
the governing organization, the number of recognized breeds varies from as few as 175
(American Kennel Club; http://www.akc.org/breeds/index.cfm) to 343 (Fédération
Cynologique Internationale; http://www.fci.be/presentation.aspx). Most breeds have a
relatively recent origin, having existed for only the past 250 years (Ostrander et al. 2008;
Parker et al. 2010). For a dog to be purebred, both of a dog’s parents must be registered

members of the same breed. Each breed therefore represents a closed population with
gene flow limited by the so-called “pedigree barrier” (Mosher et al. 2009; Patterson. 2000).
Within a breed, genetic diversity can be restricted by factors such as population
bottlenecks due to catastrophic events or breed popularity, the small number of founders
used to create a breed, and the popular sire effect (Ostrander and Kruglyak. 2000). A
consequence of these factors is an increased presence of recessive alleles within a
population. Carriers of such alleles are asymptomatic, and disease alleles can therefore be
transmitted through many generations before detection. Inbreeding to maintain
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desired traits thus results in a high frequency of autosomal recessive diseases (Ostrander.
2012; Patterson. 2000).

Although limited genetic diversity within a breed can be unfortunate for canine
health, it is this very fact that makes the dog so useful as a model for study of human
hereditary diseases and other traits that are governed genetically. Within human
populations, mutations in a large number of loci may be responsible for a single disease.
However, because of the high degree of intrabreed genetic similarity, often the analogous
disease in the dog is caused by a mutation at a single locus (Mosher et al. 2009). In
addition, the extensive linkage disequilibrium found within a breed allows for the
mapping of a disease locus using less than 10% of the markers required to map the same
locus in human populations (Lindblad-Toh et al. 2005; Sutter and Ostrander. 2004).
Dogs present with more hereditary diseases than any other non-human animal,
and nearly half of these affect only one or a few breeds (Patterson. 2000). More than 360
hereditary diseases are documented in the dog, and of these, nearly 300 are considered
models of human diseases (Mosher et al. 2009; http://omia.angis.org.au). Often, the diseases
are caused by defects in the same human and canine genes; thus, identification of the
causative mutations is equally important to veterinary medicine and human medicine
(Parker and Ostrander. 2005).

The dog is an excellent model organism because large numbers of offspring can
be produced in a relatively short amount of time, and extensive pedigree records are
maintained by breeders and owners. Humans share their homes, activities and sometimes
diet with their dogs; dogs and humans are therefore exposed to many of the same
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environmental factors (e.g., pollution, chemicals) that can affect onset of diseases,
clinical presentations and the rates of progression (Shearin and Ostrander. 2010). Medical
surveillance including preventive care and management of illnesses, and compilation of
detailed health and treatment records for dogs, is second only to that provided to humans
(Ostrander et al. 2008). Another advantage of the dog is comparable organ sizes to those of

the human. From a genetic perspective, a critical advantage of the dog as compared to
smaller model organisms (e.g., the mouse) is that diseases are naturally occurring and do
not have to be induced though knock in and knock out methodologies. Induced disease
models do not allow for the study of disease progression and may not accurately portray
the symptoms of the modeled diseases. Finally, with the exception of non-human
primates, the canine genome displays a greater degree of sequence similarity with the
human genome than other model organisms (Shearin and Ostrander. 2010).
The Canine Genome
Several notable advances in canine genomics over the past 15 years have
accelerated research for the benefit of the dog and as a model. Specifically, in 2003, a
1.5x coverage sequence of the canine genome was generated by Celera Genomics.
Canine orthologs of approximately 75% of identified human genes were represented by
reads of at least 100 continuous bases from one or more exons (Kirkness et al. 2003). A
dense radiation-hybrid gene map was generated based on the survey sequence in order to
better resolve the order of identified genes and markers (Hitte et al. 2005). Finally, a
National Institutes of Health-funded project resulted in a 7.5x sequence derived from a
purebred Boxer (Lindblad-Toh et al. 2005). The assembled genome is 2.4 giga base pairs,
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contains over 19,100 genes, and is estimated to account for 99% of the euchromatic
genome (Mosher et al. 2009). Following publication of the first build of the canine genome
assembly, a White Paper submitted to the National Human Genome Research Institute
proposed improvement of the reference genome through shotgun sequencing of larger
gaps and primer walking to fill in small- and medium-sized gaps. Approximately 1% of
the genome falls within gaps in coverage. On average, gap regions are estimated to
contain 57% GC content, likely due to the presence of CpG islands and promoter regions
(Blakesley et al. 2010).

One such gap is located on CFA25, between two genes encoding members of the
type IV collagen family, COL4A3 and COL4A4. The six type IV collagen genes are
situated in unique head-to-head arrangements on three chromosomes. Each pair of genes
shares a bifunctional promoter (see below for a detailed discussion of type IV collagen).
Sequencing of complementary DNA (cDNA) from renal tissue of a Dalmatian
determined the nucleotide sequence of the coding region of COL4A4 and a partial
transcript of COL4A3 (Wiersma et al. 2005a). Identification of exon/intron boundaries and
comparison with the human orthologs revealed that portions of the first exon of each gene
as well as the promoter region likely fall within a coverage gap.
Type IV Collagens
Six genetically distinct α chains, designated α1 (IV) through α6 (IV), make up
the collagen (IV) family and are encoded by COL4A1-COL4A6 respectively. As
mentioned previously, these genes are situated in paired head-to-head arrangements on
opposite strands of DNA: COL4A1 and COL4A2 are on CFA22 (HSA13); COL4A3 and
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COL4A4 are on CFA25 (HSA2); and COL4A5 and COL4A6 are located on the X
chromosome in both dog and human. A common promoter located between the 5′ regions
of each gene pair controls expression, although the mechanisms of expression and
regulation are not well-understood. COL4A2 is theorized to have evolved from a
duplication and inversion event of COL4A1; subsequent duplications of both genes and
their bidirectional promoters gave rise to COL4A3/COL4A4 and COL4A5/COL4A6
(Hudson et al. 1993).

Type IV collagens are integral structural components of mammalian basement
membranes found in nearly all organs. Two distinct types of α chains exist: α1-like
chains (α1, α3 and α5) and α2-like chains (α2, α4, α6). Individual α chains selfassemble into heterotrimers, or protomers, of two α1-like chains and a single α2-like
chain. Assembly of α chains occurs in only three possible combinations: α1α1α2 (IV),
α3α4α5 (IV) and α5α5α6 (IV). All three chains must be normal for formation of the
heterotrimer to occur (Boutaud et al. 2000). The α1α1α2 (IV) network is a ubiquitous
component of basement membranes throughout the body; however, distribution is tissuespecific for α3α4α5 (IV) (retina, lung, inner ear, testes and GBM of mature kidney) and
α5α5α6 (IV) (skin, testes, esophagus, smooth muscle and Bowman’s capsule of the
glomerulus) (Alexakis et al. 2006).
Each α chain has three distinct domains: a short, cysteine-rich 7S region at the
amino terminus, a central, helical, collagenous region, and a non-collagenous region
(NC1) at the carboxy terminus (Hudson et al. 2003; Ortega and Werb. 2002). Of the
subregions, the middle collagenous domain is the longest and is composed of interrupted
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repeats of a Gly-X-Y motif. X and Y residues are usually proline and hydroxyproline; the
cyclic structure of these amino acids causes a slight bend in the α chain, giving collagens
their characteristic helical form (Butkowski et al. 1987; Fagg et al. 1990; Hudson et al. 2003;
Prockop and Kivirikko. 1995). Glycine is the only amino acid with a side chain (hydrogen)

appropriately sized to fit at the center of the assembled protomer (Miner. 2011b). The NC1
domain contains a hypervariable region necessary for correct assembly of α chains into
heterotrimers (Sundaramoorthy et al. 2002).
In the glomerulus, α chain synthesis is followed by intracellular self-assembly of
protomers. Fully-formed heterotrimers are secreted into the extracellular space where
they dimerize at their NC1 domains (Abrahamson et al. 2009; Sundaramoorthy et al. 2002).
Each newly-formed dimer then links to three other dimers through their 7S domains to
form a tetramer. In this manner, the collagen (IV) network is created. During
glomerulogenesis, the collagen (IV) network in the GBM is composed of α1α1α2 (IV)
protomers. Shortly after birth, the GBM undergoes a developmental switch in which
α3α4α5 (IV) heterotrimers replace the nascent collagen network (Kalluri et al. 1997; Miner
and Sanes. 1994). Although the reason for the switch is not well-understood, it is

hypothesized that α3α4α5 (IV) protomers are more resistant to proteolytic degradation
than are α1α1α2 (IV) protomers (Abrahamson et al. 2009). Differences in membrane
strength between the α1α1α2 (IV) network and the α3α4α5 (IV) network may in part
explain the developmental isoform switch and why the nascent collagen network cannot
adequately compensate for loss of the mature α3α4α5 (IV) network. Recently, Wyss and
colleagues (2011) measured the biomechanical strength of the GBM from normal mice
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and from mouse models of early stages of AS, an inherited disease of the type IV
collagens (Wyss et al. 2011). In the AS mouse model, the GBM retains the α1α1α2 (IV)
collagen network in the absence of the α3α4α5 (IV) network (Kang et al. 2006). Prior to
the occurrence of disease-related fibrogenesis, GBM from AS mice were found to be
weaker than membranes of wild-type mice under simulated glomerular pressure
conditions (Wyss et al. 2011).
Alport Syndrome
AS is a human hereditary disorder affecting basement membranes. The primary
symptom is progressive nephropathy, with patients exhibiting increasing hematuria and
proteinuria. As glomerular filtration rate declines, the kidneys can no longer effectively
remove nitrogenous waste compounds from the blood, thus azotemia is also common
(Lemmink et al. 1997). Approximately 50% of affected human patients suffer hearing loss

and, in rare cases, ocular defects. Depending on the severity of the mutation, affected
persons usually reach ESRD by the end of their third decade and require chronic dialysis
and/or renal transplant (Atkin et al. 1988; Bekheirnia et al. 2010). The majority (~80%) of
Alport patients have the X-linked form of the disorder (XLAS), caused by mutations in
the COL4A5 gene (Barker et al. 1990; Martin et al. 1998). Mutations in COL4A3 and
COL4A4 account for the remainder of AS cases which are inherited in autosomal
recessive fashion (ARAS) or, much less frequently, in autosomal dominant manner
(ADAS) (Heidet et al. 2001; Longo et al. 2002; Longo et al. 2006; Pescucci et al. 2004; van der
Loop et al. 2000).
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The GBM is a unique, double-layered extracellular matrix and is formed from the
junction of the endothelial lining of the capillary and the podocyte cell foot processes
surrounding the glomeruli. It is composed of three uniform but distinct layers, the
thickest being the lamina densa in the middle. Under normal circumstances, in
conjunction with fenestrated endothelial cell layers, the GBM prevents proteins and blood
cells from crossing the capillary wall into the urinary space (Miner. 2012).
In AS patients, the GBM undergoes drastic ultrastructural changes observable by
transmission electron microscopy (TEM). The lamina densa loses its uniform consistency
and causes the GBM to have a “basket weave” appearance (Barsotti et al. 2001; Miner.
2011a). Some sections of the GBM become abnormally thick or thin, and podocyte

effacement creates gaps on the extracellular capillary surface, which allow albumin to
pass through the GBM into the urinary space (Abrahamson et al. 2007). Immunofluorescent
staining of glomeruli from AS patients reveals an increase in α1 (IV) chains. A lack of,
or segmental, staining for α3 (IV), α4 (IV) and α5 (IV) chains is evident in most XLASaffected males. Renal biopsies from male and female patients with ARAS or ADAS show
α5 (IV) staining of the lining of Bowman’s capsule only and a complete lack of α3
staining (Barsotti et al. 2001; Kashtan and Michael. 1996; Kashtan. 1998).
As mentioned previously, the only treatments for AS are dialysis and renal
transplantation. Renal transplants not only carry the risk of graft-versus-host disease, but
patients also face the possibility of anti-GBM nephritis (Mojahedi et al. 2007). Full length
proteins are not produced from genes harboring mutations, and therefore the immune
system does not recognize these products as self. The same antigenic regions in the NC1
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domains that enable immunostaining also serve as immunogenic targets (Kashtan and
Michael. 1996; Mojahedi et al. 2007).

Canine Models of AS
Hereditary nephropathy (HN) is a spontaneously-occurring canine analog of AS.
Dogs affected by HN suffer from proteinuria and hematuria between four and six months
of age. Azotemia is also present and becomes more severe with progression of the
disease. Invariably, HN progresses to ESRD between the ages of 12 to 18 months (Jansen
et al. 1984; Lees et al. 1998a; Lees et al. 1998b; Lees et al. 1999). Clinical signs include

anorexia, polydipsia, fatigue and vomiting but often do not present until affected dogs
reach ESRD. Deafness, which is characteristic of AS, does not occur in HN-affected dogs
(Jansen et al. 1986; Lees et al. 1998b; Lees et al. 1999). The definitive ultrastructural GBM

abnormalities observed in renal sections from AS patients are also found in samples from
HN-affected dogs. Podocyte effacement is also observed (Hood et al. 2002; Lees et al.
1998b; Lees et al. 1999; Thorner et al. 1996).

Similar to AS, the mode of inheritance of HN in the dog can be X-linked
(XLHN), autosomal recessive (ARHN) or autosomal dominant (ADHN). XLHN has been
described in both a Samoyed family (Jansen et al. 1984; Jansen et al. 1986) and a mongrel
kindred termed Navasota (NAV) dogs (Lees et al. 1999). In the Samoyed, a G to T
substitution in exon 35 of COL4A5 was found to cause a premature stop codon (Zheng et
al. 1994); affected NAV dogs harbor a 10-base pair deletion in exon 9 of COL4A5

believed to cause a truncated protein from a frameshift mutation in exon 10 (Cox et al.
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2003). Immunostaining indicated an absence of α5 (IV) expression in both families as

seen in patients with XLAS (Kashtan and Michael. 1996; Lees et al. 1999; Zheng et al. 1994).
ARHN had a devastating effect on the English cocker spaniel (ECS) breed for
over 50 years (Krook. 1957; Lees et al. 1998a; Lees et al. 1998b; Robinson et al. 1985; Steward,
AP and MacDougall, DF. 1984). In 2007, the causative mutation was identified as a

nonsense mutation in exon 3 of COL4A4 (Davidson et al. 2007). A genetic screening test
for the identified mutation was developed to aid breeders in identifying carriers. Use of
the test in conjunction with vigilant breeding practices will allow for complete removal of
the deleterious allele from the breed (Davidson et al. 2007). ARHN has also been recently
identified in the English springer spaniel (ESS), a breed closely related to the ECS
(Nowend et al. 2012). Immunostaining from affected ECS and ESS reveals a complete lack

of α3 (IV) chains while α5 (IV) chains are detected only in the lining of Bowman’s
capsule (Davidson et al. 2007; Nowend et al. 2012).
Cases of ADHN have been described in the miniature bull terrier (MBT) and
Dalmatian (Hood et al. 1995; Hood et al. 2002). Proteinuria and ocular defects were present
in affected MBT; however, hematuria was not observed in all affected dogs. In the GBM,
multilamellation and thickening were observed, consistent with other canine models of
AS. Onset of ESRD in MBT is more widely variable than in other forms of HN and
ranges from several months to ten years (Hood et al. 1995). Although the genetic cause of
ADHN in MBT has not been identified, COL4A3, COL4A4 and MYH9 have been
eliminated as candidate genes (O'Leary et al. 2009). Clinical signs of ADHN in the
Dalmatian are similar to those observed in MBT, although glomerular abnormalities are
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not as severe and ocular defects were not present. The causative mutations for these
breeds are unknown, and immunostaining of GBM did not reveal any difference in any
type IV collagen α chains between normal and affected dogs of either breed (Hood et al.
2000; Hood et al. 2002). The genetic causes of ADHN are expected to be different in the

MBT and Dalmatian but all affected animals within a breed are expected to share the
same mutation (Hood et al. 1995; Hood et al. 2002).
The Dog as a Model for Gene Therapy
Although gene therapy is not currently an option for human AS patients, progress
has been made toward developing treatment options (Gross et al. 2009). The process for
effective glomerular vector delivery (Heikkila et al. 1996) is quite complicated. Therefore
recombinant α5 (IV) chain expression was performed in the bladder of XLHN-affected
dogs (Harvey et al. 2003). Despite normal bladder function in XLAS- and XLHN-affected
individuals, this organ normally expresses α5α5α6 (IV) chains and is easily accessible
for adenoviral injection and thus was chosen for gene therapy experiments (Harvey et al.
2003). More recently, AS therapies involving stem cell transfer are being developed in

ARAS mouse models with promising results (Katayama et al. 2008; LeBleu et al. 2009).
Although mouse models of human disease are not necessarily ideal, novel therapies
developed in such models followed by preclinical validation in a dog model will be of
great benefit if we are to progress to human trials.
Successful gene therapy in the dog has led to human clinical trials for several
hereditary diseases: leukocyte adhesion deficiency-1 (LAD-1) (Bauer and Hickstein. 2000),
Lebers congenital amaurosis (Acland et al. 2001; Acland et al. 2005; Amado et al. 2010;
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Maguire et al. 2008), Gaucher’s disease (Novelli and Barranger. 2001), Duchenne muscular

dystrophy (Aartsma-Rus et al. 2004; Kinali et al. 2009; Shimatsu et al. 2003), hemophilia A
(Powell et al. 2003) and hemophilia B (Manno et al. 2006; Xu et al. 2003). Although human

gene therapy trials existed for LAD-1 prior to the initiation of canine research, a lentiviral
vector construct conferring less genotoxicity than previously used viral vectors was
developed using in a canine model of LAD-1 (Bauer et al. 2011; Nelson et al. 2010). In
addition, the treatment of Leber’s congenital amaurosis using gene therapy led to the
initiation of a human clinical trial (Maguire et al. 2008), and results of therapy developed
for achromatopsia appear promising for future human trials (Komaromy et al. 2010).
This project had two major objectives. The first objective was to sequence the
first exons and shared promoter region of COL4A3 and COL4A4 to fill in the gap in the
reference sequence of CFA25. The second objective was to identify and characterize the
mutation causative for ARHN in the ESS.
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CHAPTER II
SEQUENCING OF THE CFA25 GAP AND 5′ REGION OF CANINE COL4A3

Overview
The canine genome reference sequence is an invaluable resource for genetic
studies. While the assembly covers 99% of the genome, there are gaps that leave the
remaining 1% without coverage. The region between COL4A3 and COL4A4 has poor
coverage, with gaps that include the first exons of each gene and a shared bifunctional
promoter. These genes encode structural basement membrane proteins critical for
glomerular filtration and are sites of mutations implicated in hereditary renal disease. To
better understand the role of the COL4A3 and COL4A4 gene products in kidney disease,
it is important to characterize each gene as well as their common promoter. Herein, the
identification of the first two exons of COL4A3 is reported.
Introduction
The canine genome sequence was assembled from whole genome shotgun reads
with an average of 7.5x coverage for the majority of the genome. This assembly covers
approximately 99% of the euchromatic regions of the genome (Lindblad-Toh et al. 2005). It
is estimated that just less than 1% of the genome still remains within gaps between
assembled contigs. These regions are characterized by higher than average GC content
and repetitive sequences (Blakesley et al. 2010). Next-generation sequencing technologies
have allowed for greater sequence coverage through gap regions; however, in a recent
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study, nearly 60% of newly-acquired contigs were not able to be mapped to the reference
genome (Kim et al. 2012).
A gap in coverage estimated to span approximately 500-base pairs is located on
CFA25, between COL4A3 and COL4A4. As with the other type IV collagen pairs,
COL4A1/COL4A2 and COL4A5/COL4A6, COL4A3 and COL4A4 are situated in a headto-head arrangement on opposite strands of DNA and share a common bifunctional
promoter (Momota et al. 1998; Wiersma et al. 2005a). Specific protomers composed of three
type IV collagen α chains are crucial structural and functional components of the GBM
in both the fetal (α1α1α2) and mature (α3α4α5) kidney (Kalluri et al. 1997). A defect in
any individual gene encoding an α chain prevents formation of the heterotrimer, resulting
in degeneration of GBM function and ultimately renal failure (Boutaud et al. 2000). To
effectively understand the full involvement of the type IV collagens in hereditary renal
disease(s), it is necessary to have the full sequences available of each gene pair, and also
the associated promoter regions.
In an effort to identify the genetic variation responsible for an inherited
nephropathy in the Norwegian Elkhound, Wiersma and colleagues (2005) sought to
characterize the mRNA sequences for COL4A3 and COL4A4 (Wiersma et al. 2005a;
Wiersma et al. 2005b). Using 5′ rapid amplification of cDNA ends (RACE), the sequence

of the coding and 3′ untranslated regions of COL4A4 were identified (GenBank accession
number AY263363.1). A partial mRNA sequence of COL4A3 was determined through
primer-walking techniques (GenBank accession number AY263362.1); however, the
identified coding region lacked the 5′ untranslated region and a transcription start site
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(Wiersma et al. 2005a). Comparison with human COL4A3 intron/exon boundaries using

GENATLAS (http://genatlas.medecine.univ-paris5.fr/) indicated the missing regions
corresponded to exon 1 and partial exon 2.

Figure 2.1 Multispecies alignment of COL4A3 exon 1. The nucleotide alignment is in the upper
region. “*” indicates identical bases in all four species. The protein alignment is in the lower
region. “*” indicates exact matches, “:” indicates conservative substitutions, and “.” indicates
semi-conservative substitutions. A highly conserved region used to design a degenerate primer
(4A3-DF2) is highlighted in yellow.

The objective of this study was to amplify and sequence the promoter and the 5′
end of COL4A3. The human coding region of COL4A3 shares 86% identity at the
nucleotide level and 83% identity at the amino acid level with the canine ortholog and
thus is a useful reference for primer design and sequence verification (Wiersma et al.
2005a). Alignment of published sequences of COL4A3 exon 1 from human and three

additional mammals by ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) indicated
regions of high conservation at both the nucleotide and protein levels (Figure 2.1).
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Degenerate primers were designed based on regions of exon 1 showing the highest
conservation between all four organisms. Through amplification and direct sequencing
optimized for GC-rich regions, partial coding sequences of exons 1 and 2 of canine
COL4A3 were identified and validated by comparison to the published human COL4A3
sequence.
Materials and Methods
Amplification and Sequencing
To amplify the first exon of COL4A3, degenerate forward primers were designed
based on the consensus sequence from a multispecies alignment of exon 1 and paired
with reverse primers annealing to a region of the coding sequence corresponding to exons
6 and 7 (GenBank accession number AY263362.1). All primer sequences are listed in
Table 2.1. Each 25 µl reaction contained 2.5 µl 10X Taq DNA polymerase buffer B
(Fisher Scientific, Pittsburgh, PA), 50 pmol of each primer, 0.2 mM of each dinucleotide
triphosphate, 1M betaine (Sigma-Aldrich; St. Louis, MO), 5% dimethylsulfoxide, 1.5
mM magnesium chloride and 2.0 units of Taq DNA polymerase (Fisher Scientific;
Pittsburgh, PA). Complementary DNA reverse transcribed from clinically normal renal
RNA was used as template for all reactions. Amplification was performed under the
following conditions: 94°C for 5 minutes, 35 cycles of 94°C for 1 minute, 55°C for 1
minute, and 72°C for 1 minute, and a single cycle of 72°C for 10 minutes.
PCR products were assessed by agarose gel electrophoresis. Products of correct
sizes were excised from the agarose and purified using a commercially available kit (5
PRIME; Gaithersburg, MD). Purified amplicons were sequenced using Big Dye
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Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems; Foster City, CA) and
resolved on an ABI 3730 Genetic Analyzer (Applied Biosystems; Foster City, CA).
Table 2.1 Primers and melting temperatures (°C) used for polymerase chain reaction
Primer Name
Sequence
Tm
COL4A3
4A3-DF2*
CTGYTGSTRCTCCTGGCK
58.1
4A3-R14
CCTGTGGTCCAGGCAAGC
59.2
4A3-R15
CAGGAGAACCAGCAGGTCCA
59.1
Gap Region

COLP-F
4A3-R16

GCACCAACAAAAAATCTGGGCAC
CGCCAGGAGCACCAACAG

4A3-DF3*
ATGAGCSCCCGGACSGCS
COLP-R
CAGGAACACGAACAGCAGCATC
*Primer contains degenerate bases. Standard International Union of
Biochemistry (IUB) nomenclature rules were used in designating degenerate
bases: Y (T, C); S (G,C); R (A,G); K (G,T).

65
64.7
71.5
65

Subsequent reactions were based on methods described by Musso and colleagues
(2006) to amplify GC-rich templates using PCR additives (Musso et al. 2006).
Amplification was performed using primers based on experimental sequence obtained
above paired with primers flanking the gap region (Table 2.1). Each reaction contained
100 ng of canine genomic DNA, 2.5 µl 10X Taq DNA polymerase buffer B (Fisher
Scientific, Pittsburgh, PA), 10-50 pmol of each primer, 0.2 mM of each dinucleotide
triphosphate, 1.3 M betaine (Sigma-Aldrich; St. Louis, MO), 5% dimethylsulfoxide, 50
µM 7-deaza-dGTP, 2.5 mM magnesium chloride and 1.25 units of Taq DNA polymerase
(Fisher Scientific; Pittsburgh, PA) in a total volume of 25 µl. Cycling conditions were
94°C for 5 minutes; 40 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for
45 seconds; followed by a single cycle of 72°C for 5 minutes.
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Reaction products were isolated and purified as described above. Direct
sequencing reactions using a 3:1 mix of BigDye Terminator v3.1 Cycle Sequencing and
dGTP BigDye Terminator v3.0 Reaction Ready Cycle Sequencing kits (Applied
Biosystems; Foster City, CA) were carried out by the Clemson University Genomics
Institute. Sequencing results were resolved on an ABI 3730 Genetic Analyzer (Applied
Biosystems; Foster City, CA).
Sequence Analysis
Sequencing data were analyzed using Ridom TraceEdit sequencing software
(Ridom, Inc., Würzburg, Germany). Canine sequences obtained from amplification using
degenerate PCR were aligned with the 5′ coding regions of the human COL4A3 mRNA
sequence (GenBank accession number NM_000091.4) and the previously mentioned
partial canine COL4A3 mRNA to verify identity.
Results and Discussion
In general, promoter regions are GC-rich due to the presence of CpG islands.
Because of the proline content in the Gly-X-Y motif found in the collagenous domain,
type IV collagens also have a high GC content (Prockop and Kivirikko. 1995). A number of
different methods using PCR additives and GC-optimized cycling were attempted to
amplify and sequence the 5′ untranslated and coding regions of both COL4A3 and
COL4A4 as well as the shared promoter region. The use of PCR enhancers including
betaine and DMSO in combination with degenerate primers and increased Mg2+
concentration allowed for effective amplification of a short region of COL4A3 from a
GC-rich template. Alignment with the published human COL4A3 mRNA sequence
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showed that the 298-base pair degenerate PCR amplicon contained the last 39 base pairs
of COL4A3 exon 1 and the first 32 base pairs of exon 2 (Figure 2.2). The remaining 227
base pairs of amplified sequence aligned both with COL4A3 sequencing results obtained
previously (Nowend et al. 2012) and the published canine reference sequence (data not
shown).

Figure 2.2 Alignment of canine COL4A3 sequencing results with the published human COL4A3
5′ mRNA sequence. Nucleotides corresponding to the start codon in the human sequence are
indicated in red. Exons 1 & 2 are labeled and separated by a vertical black line. “*” indicates
identical nucleotides in both sequences.

Using the methods described above, it was not possible to determine sequences of
the promoter, the remaining sequence of COL4A3, or the 5′ untranslated region of
COL4A4. While amplification using primers flanking the gap region produced amplicons,
the resulting products proved intractable to direct sequencing, likely due to the high GC
content of the region. Amplification using COL4A3-specific primers in combination with
the gap-flanking primers produced products; however, none of these aligned with
published sequences of COL4A3 exon 1 from human, rhesus, mouse, or rat (data not
shown).
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Efforts to amplify and sequence across the gap in sequence of CFA25 are
ongoing. Determining the full sequences of COL4A3 and COL4A4 as well as the shared
promoter would contribute to the characterization of hereditary renal diseases in different
breeds of dog. In addition, successful sequencing through the undetermined region of
CFA25 would assist in efforts to read through the gaps in the canine genome and improve
this genomic tool.
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CHAPTER III
CHARACTERIZATION OF THE GENETIC BASIS FOR AUTOSOMAL RECESSIVE
HEREDITARY NEPHROPATHY IN THE ENGLISH SPRINGER SPANIEL*

Overview
Autosomal recessive hereditary nephropathy (ARHN), a fatal juvenile-onset renal
disease, was diagnosed in two English Springer Spaniels (ESS) based on transmission
electron microscopy and immunostaining of kidney. A closely related breed, the English
Cocker Spaniel (ECS), has been affected by ARHN for more than 50 years. Recently, the
causative mutation of ARHN in the ECS was identified. The ESS does not have the ECS
mutation, and so additional genetic analyses were performed. Expression levels of
COL4A3, COL4A4 and COL4A5 in the renal cortex were determined using quantitative
reverse transcription polymerase chain reaction (qRT-PCR) for ARHN-affected dogs and
7 other dogs for comparison. qRT-PCR indicated reduced mRNA transcript expression of
both COL4A3 and COL4A4 in the kidney of ARHN-affected ESS when compared to
those of unaffected dogs. The coding regions of COL4A3 and COL4A4 were sequenced
for both ARHN-affected dogs and an unaffected dog. Sequencing revealed a single
nucleotide substitution in COL4A4 at base 2806. This results in a premature stop codon in

*Portions of this chapter are reprinted with permission from “Characterization of the
Genetic Basis for Autosomal Recessive Hereditary Nephropathy in the English Springer
Spaniel” by K. Nowend, A. Starr-Moss, G. Lees, B. Berridge, F. Clubb, C. Kashtan, M.
Nabity and K. Murphy, 2012. Journal of Veterinary Internal Medicine, 26, 294-301,
Copyright 2012 by John Wiley & Sons, Inc.
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exon 30. Direct sequencing of exon 30 was done for 63 ESS. Fourteen related dogs were
identified as carriers of the mutation, including both parents of the affected dogs. C2806T
is a novel mutation causing ARHN in the ESS, a breed not previously reported to be
affected by ARHN.
Background
Hereditary nephropathy (HN) is a progressive fatal renal disease that has been
identified in several domestic dog breeds or kindreds. The disease was first described as
renal cortical hypoplasia (Krook. 1957), and also has been called familial nephropathy
(Lees et al. 1998a; Lees et al. 1998b; Robinson et al. 1985; Steward, AP and MacDougall, DF.
1984) and hereditary nephritis (Hood et al. 1995; Hood et al. 2002; Lees et al. 1998b) in

various published accounts. HN is the result of glomerular basement membrane (GBM)
defects that alter GBM structure and function in the mature kidney. The GBM is a sheetlike layer of extracellular matrix that lies between and supports the endothelial and
visceral epithelial cell components of the glomerular capillary walls. This structure is
primarily composed of heterotrimers of laminins and type IV collagens (α1-α5 chains).
During glomerular development, the GBM is initially composed of α1α1α2(IV)
heterotrimers, but as the glomeruli mature, α3α4α5(IV) heterotrimers gradually replace
the α1α1α2(IV) network. Moreover, normal synthesis and assembly of α3α4α5(IV)
heterotrimers is crucial for maintaining the structure and function of the GBM in adult
kidney. Defects in any of the genes encoding α3(IV), α4(IV), or α5(IV) collagen chains
can cause the GBM to develop distinctive abnormalities during adolescence that initiate a
progressive renal disease culminating in juvenile-onset chronic renal failure (Khoshnoodi
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et al. 2008). In humans, the nephropathy caused by type IV collagen defects is usually

called Alport syndrome and is associated with certain hearing and ocular abnormalities in
many affected individuals. In both humans and dogs, type IV collagen-related renal
disorders have both X-linked and autosomal patterns of inheritance. This is because the
COL4A5 gene is on the X-chromosome and the COL4A3 and COL4A4 genes are on an
autosome (chromosome 2 in humans and chromosome 25 in dogs) in both species. For
these reasons, COL4A3, COL4A4 and COL4A5 are candidate genes for identifying the
causative mutations in subjects with HN.
An autosomal recessive form of HN (ARHN) has occurred in the English Cocker
Spaniel (ECS) for more than 50 years (Krook. 1957; Lees et al. 1998a; Lees et al. 1998b;
Robinson et al. 1985; Steward, AP and MacDougall, DF. 1984). Affected dogs typically

develop severe (end-stage) renal disease by the time they are 6 to 24 months of age. In
dogs with ARHN, clinical signs often are not observed until late in the course of disease
(Lees et al. 1998a; Lees et al. 1998b), although proteinuria invariably develops a few

months before other clinicopathologic changes can be detected. There is no cure for HN;
all currently available treatments are symptomatic or supportive in nature. Previous work
identified the mutation in COL4A4 that causes ARHN in ECS (Davidson et al. 2007).
Efforts to eliminate the disease from the ECS breed using genetic testing coupled with
careful breeding practices (i.e. preventing the breeding of 2 carriers) are ongoing and
have been highly successful.
The English Springer Spaniel (ESS) is closely related to the ECS and, according
to the American Kennel Club, originally came from the same litters (http://www.akc.org).
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Despite common ancestry, ARHN has not been described previously in the ESS breed.
This report describes the discovery of ARHN in a family of ESS and subsequent
identification of a novel COL4A4 mutation in this kindred.
Materials and Methods
Clinical and Pathologic Evaluations
Two female ESS littermates were evaluated at the Texas A&M University
College of Veterinary Medicine and Biomedical Sciences (TAMU-CVM) for renal
disease that was first detected when the dogs were 7 months old. Each dog’s renal disease
was observed to progress to a near-terminal stage over the next 2-3 months, whereupon
each dog was euthanized.
Clinical examinations, laboratory testing, and diagnostic imaging of the 2 dogs
were performed by conventional methods. Pathologic evaluations of kidney obtained
immediately after euthanasia included histologic, ultrastructural, and immunostaining
examinations utilizing methods similar to those previously described (Lees et al. 1998b).
Formalin-fixed tissue was routinely embedded in paraffin and sections cut 3 microns
thick were prepared with H&E, PAS, Jones’ methenamine silver, and Masson’s trichrome
stains for light microscopic examination. Cortical tissue for transmission electron
microscopic examination was fixed in chilled 3% glutaraldehyde, further processed,
sectioned and stained by conventional methods (Lees et al. 1998b), and examined in a
JEOL TEM-1230 transmission electron microscope. Immunolabeling of renal basement
membranes for their content of certain collagen IV proteins was performed with indirect
immunofluorescence staining methods using monoclonal antibodies specific for α1/2
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chains (MAB M3F7), α3 chains (MAB A2), or α5 chains (MAB A7), as previously
described (Lees et al. 1998b).
Samples for Molecular Genetic Evaluation
Whole blood and kidney tissue were collected from both affected ESS. DNA was
extracted from whole blood using a commercially available kit (Gentra Puregene Blood
Kit; Qiagen Inc., Valencia, CA), and renal tissue was stored in an RNA stabilization
solution (RNAlater; Applied Biosystems/Ambion, Austin, TX). Additional blood
samples were collected from 25 related ESS (including both parents) and 1 unrelated ESS
owned by the breeder. Subsequently, DNA was isolated from buccal cell samples from
35 ESS, unrelated to the kindred, obtained from owners.
RNA was extracted from the kidney tissues of the 2 affected ESS, as well as from
archived frozen kidney tissue from 2 ARHN-affected ECS, 2 XLHN-affected mixedbreed (NAV) dogs (Cox et al. 2003) and 3 mixed-breed dogs unaffected by any form of
HN. Reverse transcription was performed to synthesize complementary DNA (cDNA)
from the RNA. The ESS were client-owned; breed-matched tissue samples from
unaffected dogs were not available. DNA and RNA quantification was determined using
a spectrophotometer (NanoDrop; Fisher Scientific, Pittsburgh, PA).
Genomic Screening of COL4A4 Exon 3
Exon 3 of COL4A4 was amplified by polymerase chain reaction (PCR) to screen
for the previously identified ARHN mutation (Davidson et al. 2007) using genomic DNA
from the 2 affected ESS and 3 ECS with known clinical status: 1 ARHN-affected dog, 1
ARHN-carrier and 1 unaffected dog. Each reaction contained 12.5 µl 2x all-inclusive
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PCR premix (ReddyMix Master Mix; AbGene, Rochester, NY), 0.25 µM of each primer
and 50 ng of DNA, brought to a final volume of 25 µl with sterilized water. Primer
sequences and cycling conditions have been published previously (Davidson et al. 2007).
Product sizes were verified using agarose gel electrophoresis. The PCR amplicons were
treated with 0.5 units of Exonuclease I (New England Biolabs, Ipswich, MA) and 0.25
units of shrimp alkaline phosphatase (Promega, Madison, WI). Purified amplicons then
were sequenced (Big Dye Terminator v3.1 Cycle Sequencing Kit; Applied Biosystems,
Foster City, CA) and resolved (ABI 3730 Genetic Analyzer; Applied Biosystems, Foster
City, CA).
Quantitative Reverse Transcription-PCR (qRT-PCR)
mRNA transcript numbers of COL4A3, COL4A4, and COL4A5 were quantified
for 9 dogs: 2 ESS and2 ECS with ARHN, 2 NAV dogs with XLHN and 3 dogs
unaffected by any form of HN. Primer/probe assays (TaqMan Gene Expression Arrays;
Applied Biosystems, Foster City, CA) specific to C. familiaris and spanning 2 exons
were selected for qRT-PCR. Probes were labeled at the 5′ end with 6-carboxyfluorescein
(6-FAM) and at the 3′ end with a nonfluorescent quencher. Each 25 µl reaction contained
12.5 µl 2X QuantiTect Probe RT-PCR Master Mix (Qiagen Inc., Valencia, CA), 0.25 µl
QuantiTect RT Mix (Qiagen Inc., Valencia, CA), 0.72 nM of each primer, 0.2 nM of
probe and 7 ng of RNA. Reverse transcription, amplification and detection were
performed (BioRad iQ5 Real-Time PCR Detection system; BioRad Inc., Heracles, CA)
under the following cycling conditions: reverse transcription at 50°C for 30 minutes and
inactivation at 95°C for 13 minutes 30 seconds, followed by 45 cycles of 94°C for 15
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seconds, 60°C for 60 seconds and 70°C for 30 seconds. All reactions were performed in
triplicate. For each sample, quantification of collagen mRNA transcripts was determined
by normalization against β-actin mRNA transcript numbers, and the magnitude of change
between groups was analyzed using the Pfaffl method (Pfaffl. 2001). Any changes in
transcript numbers greater than 2-fold were considered significant.
COL4A3 and COL4A4 cDNA Sequencing
Amplification of the coding regions of COL4A3 and COL4A4 was performed for
both affected ESS and a normal control dog. RNA was reverse transcribed (High
Capacity Reverse Transcription kit; Applied Biosystems, Foster City, CA), and the
resulting cDNA was used as a template for amplification. Amplicons were 500-base pairs
(bp) long and designed to overlap by approximately 75 bp at each end, spanning the
coding regions for both genes (see Table 3.1 for primer sequences). Each 25 µl reaction
contained 3-5 µl of cDNA, 2.5 µl of 10X Taq DNA polymerase buffer B (Fisher
Scientific, Pittsburgh, PA), 2.0 units of Taq DNA polymerase (Fisher Scientific,
Pittsburgh, PA), 0.2 mM of each dexoynucleotide triphosphate, 1.5 mM magnesium
chloride, 0.4 µM of each primer, 1 M betaine (Sigma-Aldrich, St. Louis, MO) and 5%
dimethyl sulfoxide. PCR amplification was carried out under the following conditions: a
single cycle at 94°C for 5 minutes, 35 cycles of 94°C for 1 minute, 50-54°C for 1 minute,
and 72°C for 1 minute, and a single cycle of 72°C for 10 minutes. Purified amplicons
were sequenced and analyzed as described above.
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Table 3.1. Primers and melting temperatures (°C) used for polymerase chain reaction amplification of canine COL4A3 and COL4A4
Primer Set
Tm
Sequence
Primer Set
Tm
Sequence
COL4A3-1
56 GCTTTCCTGGACCTGCTG
COL4A4-1
57 GTCCCAAGACTTGACTGTGAGG
GCGTCACAATAACTGTTCCTGG
GTCACCCTGAATACCTTTAATGGCA
COL4A3-2
54 GCCACAGAAGGTATAGAACTTGA
COL4A4-2
56 GGCTACAATGGTTCACGAGGT
CAGCACTTCCAAGAACTCCAG
TGGTCCAATTCCAGGTTCTCC
COL4A3-3
53 GGTGAAGACGGCATTAAGG
COL4A4-3
56 GTACAGCCACCTGATTCCTGT
CCTCAGGCTCAGATGTTTCTC
GGACTTAAATCCGCTCTCCCTG
COL4A3-4
54 CTCTTGTGCGTACAGTGTGC
COL4A4-4
57 ACTATGGAGAAATGGGGTCCGT
GGATACCAGGTGGACCTC
GTTGTCCTGGAAATCCTGGGAG
COL4A3-5
52 CAAACTATGGACCACAGGG
COL4A4-5
56 ACCTGGCAGCAAAGGAGAA
CTGGTTGCCCTTCCAATCCAT
CTCCCATGTCACCACGAAAAC
COL4A3-6
54 GGACTAGCCATACCTGGAGA
COL4A4-6
57 AGGGTTGAGGTGCTTGGATG
GTCCTTTCTCTCCTTCTTCCC
CCTGGGACTCCTGGGAATC
COL4A3-7
55 GGTCATCGAGGTGAGATAGGA
COL4A4-7
57 AGGTTGGAAAGGACAGCGAG
CTTGGAGACCATGAACACCTG
CTCTCAGCCCAGGTGAGC
COL4A3-8
56 CAGGCAGCATTGGGAATCC
COL4A4-8
57 AGCACCTGGATTTCACAGAGG
AGTCCCGTCATGCCAGTG
AGCACCTTTGGCTCCTTTCTG
COL4A3-9
55 CTATGGGCATGAGAGGCAAC
COL4A4-9
56 AAGAGGCATGATGGGAGATCC
GATCTTAACTGTGCCAGGGTCTC
CATCGCATCCTGGGAAGC
COL4A3-10
52 GTCTACCTGGAACTGTGG
COL4A4-10 57 GAGCGTTGACCTTCTGAGAGG
CTGCCGAGAGTTCCCAAGTC
GAAGCCACTGAGGTATCCAGG
COL4A3-11
52 CCTGGATTAGATGGACTGC
COL4A4-11 56 CCCAAGAGGACCAGAAGGAG
ATGAGGGAATGTCAGTGGT
TCTGAGAGCGGCATCATGG
COL4A3-12
54 GCACTGTCTGTGAAGGTCC
COL4A4-12 57 ACCAAGTGTGCCACTACGC
GAAACTCTGCAAGAGCACAAG
ACTGGAGTCTGAAATGAGCACC
Tm, melting temperature

Genomic Screening of COL4A4 Exon 30
PCR amplification of exon 30 of COL4A4 was performed as above for exon 3
using genomic DNA from the 2 affected ESS and 61 ESS of unknown status. Cycling
conditions were as follows: 94°C for 5 minutes, 35 cycles of 94°C for 1 minute, 54°C for
1 minute, and 72°C for 1 minute, and 1 cycle of 72°C for 10 minutes. PCR products were
treated with 0.5 units of Exonuclease I and 0.25 units of shrimp alkaline phosphatase, and
then sequenced and analyzed as described for exon 3 above.
Results
Clinical Findings
The 2 female ESS littermates (Dog 14 and Dog 15*) were owned by 1 individual
who did not observe any signs of ill health before taking them to a veterinarian to be
spayed at 7 months of age. Laboratory tests performed then showed that both dogs had
marked proteinuria (Dog 14: USG, 1.036; UPC, 7.9, and Dog 15: USG, 1.042; UPC, 7.0).
Both dogs were mildly hypoalbuminemic (Dog 14: SA, 2.2 g/dL, and Dog 15: SA, 2.5
g/dL; reference range, 2.7-4.4 g/dL). Dog 14 also was mildly azotemic (BUN, 48 mg/dL;
reference range, 6-25 mg/dL; and SCR, 1.6 mg/dL; reference range, 0.5-1.6 mg/dL), and
values for Dog 15 (BUN, 38 mg/dL; SCR, 1.3 mg/dL) were borderline high.
Additional testing performed 2 months later showed persistent proteinuria and
progression to renal failure in both dogs, albeit more rapidly in Dog 14 (UPC, 9.8; BUN,
119 mg/dL; SCR, 6.2 mg/dL; and SA, 2.2 g/dL) than in Dog 15 (UPC, 8.1; BUN, 65
mg/dL; SCR, 3.0 mg/dL; SA, 2.2 g/dL). A renal ultrasound examination of Dog 14
*In keeping constant with the numbering of the dogs in Figure 5, the affected ESS are
referred to as Dogs 14 and 15.
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showed hyperechoic cortices with normal corticomedullary definition in both kidneys.
Renal ultrasound findings for Dog 15 were similar except that the left kidney also
exhibited a large wedge-shaped cortical defect that was thought likely to be the site of a
previous infarct, and the right kidney was appreciably larger (about 1.5 cm longer) than
the left kidney.
One week later, Dog 14 began exhibiting uremic signs and was brought to
TAMU-CVM for euthanasia and postmortem examination of the kidneys. When
examined, the dog was weak and moderately dehydrated. Laboratory tests performed on
this occasion showed severe azotemia (BUN, 203 mg/dL; SCR, 11.3 mg/dL) and
persistent proteinuria (USG, 1.021; UPC, 9.8).
Dog 15 remained clinically well for 1 additional month despite increasing
azotemia (SCR concentration increased from 3.0 to 4.4 mg/dL over a 12-day interval)
before the dog became lethargic and began vomiting. The dog then was brought to
TAMU-CVM for euthanasia and postmortem examinations of the kidneys. The dog had a
subdued demeanor and was marginally dehydrated when examined, and laboratory tests
showed azotemia (BUN, 82 mg/dL; SCR, 6.2 mg/dL) and persistent proteinuria (USG,
1.016; UPC, 11.9).
Pathologic Findings
The gross appearance of both kidneys of Dog 14 was similar. They were
symmetrically shaped and had smooth capsular contours. However, the kidneys of Dog
15 were not symmetrical; the left kidney was smaller than the right, and its middle third
was smaller than its poles.
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Histologic examination disclosed similar severe changes in the glomeruli and
tubulointerstitium of both dogs. Glomeruli had thickened and often laminated Bowman's
capsules. Glomerular tufts were lobulated and markedly hypercellular with widespread
mesangial expansion and effacement of peripheral capillary loops. Hypercellularity
within glomeruli consisted of increased numbers of mesangial cells coupled with
hypertrophy of endothelia as well as visceral and parietal epithelial cells. Where present,
patent glomerular capillary loops frequently were circumscribed by mildly to moderately
thickened walls. Glomerular adhesions to Bowman's capsule (synechia) were common,
and occasionally glomerular adhesions were accompanied by crescents of increased cells
at the interface of the adherent glomerular tuft and the thickened capsule. Hyaline
eosinophilic amorphous coagula and eosinophilic globular material were common within
the urinary space. The cortical interstitium was diffusely and mildly to moderately
expanded by dense to regionally loose (edematous) collagenous connective tissue
containing widely scattered infiltrates of predominantly mixed mononuclear
inflammatory cells. Cortical tubules often were mildly dilated and lined by mildly
attenuated epithelia. Tubular dilatation also was regionally accentuated and often most
prominent in distal segments. Eosinophilic proteinaceous fluid and protein casts were
commonly present within tubular lumina and extended into the medulla. The medulla was
diffusely and homogenously expanded by dense collagenous connective tissue containing
widely scattered small foci of mixed mononuclear inflammatory cells.
Ultrastructural evaluation of the glomeruli identified diffuse effacement of
visceral epithelial cell foot processes. Glomerular capillary walls exhibited multifocal
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wrinkling and mesangial cell interpositioning. Basement membranes within the
glomerular capillary walls were globally thickened due to distortion of the lamina densa,
which was characterized by longitudinal splitting and fragmentation that created the
appearance of a “net-like” or “woven” pattern (Figure 3.1A). Mesangium had increased
cells and matrix.

Figure 3.1 Transmission electron photomicrograph of a glomerular capillary loop from an
ARHN-affected ESS (dog 15; panel A) that shows marked thickening of the glomerular basement
membrane with longitudinal splitting and fragmentation of its lamina densa, as compared with a
capillary loop from a normal dog (panel B).
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Figure 3.2 Fluorescence photomicrographs showing immunolabeling of renal sections from an
ARHN-affected ESS (Dog 14; panels A, C, and E) compared with that for a normal dog (panels
B, D, and F) for α1/2 chains (panels A and B), α3 chains (panels C and D), or α5 chains (panels
E and F) of collagen IV. Panel A shows increased labeling of α1/2 chains, especially in the
capillary walls, compared with normal dog kidney (Panel B). In panel C, which shows completely
negative labeling for α3 chains in the ARHN-affected dog, half of the microscopic field is shown
with phase-contrast illumination to verify presence of a glomerulus at that location. The negative
labeling for α3 chains contrasts with the uniformly positive labeling of the normal dog’s
glomerular capillary walls for α3 chains (Panel D). Panel E shows labeling of the affected dog’s
capillary walls for α5 chains that is substantially reduced in its intensity and extent compared
with the labeling of the normal dog’s glomerular capillary walls for α5 chains (panel F).
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Immunostaining of kidneys from both Dog 14 and Dog 15 produced similar
results that demonstrated an abnormal pattern of expression of type IV collagens in their
glomeruli (Figure 3.2). Labeling of GBM for α3 chains was completely absent (Figure
3.2C - D), whereas labeling for α5 chains was present but of decreased fluorescent
intensity compared with normal dog kidney (Figure 3.2E - F) and labeling for α1/2
chains was increased (Figure 3.2A-B). This pattern of abnormal expression of type IV
collagens in GBM was identical to that previously observed in ECS with ARHN
(Davidson et al. 2007; Lees et al. 1998b).

Taken together, the pathologic findings were sufficient for an unequivocal
diagnosis of ARHN in both affected ESS (Dog 14 and Dog 15) and identified COL4A3
and COL4A4 as candidate genes in which the underlying causative mutation was
expected to exist in the dogs’ kindred.
Genomic Screening of COL4A4 Exon 3
Exon 3 was sequenced and analyzed from the ARHN-affected ESS and compared
to the sequences obtained from ECS of varying ARHN status to determine if this disease
in ESS was caused by the same mutation identified in ECS. All sequences were aligned
with the published genomic sequence (CanFam 2.0; (Lindblad-Toh et al. 2005)) for
reference. Neither ARHN-affected ESS possessed the nonsense mutation found in
affected and carrier ECS (data not shown).
Quantitative Reverse Transcription-PCR
Transcript quantities of COL4A3, COL4A4 and COL4A5 mRNA were evaluated
with qRT-PCR. Relative to unaffected dogs, quantities of COL4A3 and COL4A4 mRNA
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transcripts were decreased 14.33-fold and 10.60-fold respectively, in the kidneys of
ARHN-affected ESS. COL4A5 mRNA numbers in kidneys of affected ESS were not
significantly different from those seen in unaffected dogs (Figure 3.3).

Figure 3.3 Quantitative reverse transcription PCR analysis of COL4A3, COL4A4 and
COL4A5 mRNA transcript levels revealed a 14.33- and 10.6-fold decrease of COL4A3
and COL4A4, respectively, in ARHN-affected ESS compared to mRNA levels in normal
dogs. Transcript levels of COL4A5 were not significantly different between the 2 groups.

COL4A3 and COL4A4 cDNA Sequencing
To identify the causative mutation of ARHN in ESS, overlapping 500-bp
segments spanning the coding regions of both COL4A3 and COL4A4 were sequenced.
For comparison, cDNA from an unaffected, mixed-breed dog was sequenced with the
same primer sets. All sequences were aligned with the published mRNA sequences for
COL4A3 (GenBank accession number AY263362.1) and COL4A4 (GenBank accession
number AY263363.1). A single nucleotide substitution was found at base 2806 in
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COL4A4, changing a cytosine to a thymine in a region corresponding to exon 30. This
substitution creates a nonsense mutation and is predicted to change the glutamine at
position 904 to a stop codon, resulting in a prematurely truncated transcript (Figure 3.4).
No other deleterious mutations were found in the coding sequences of either gene.

Figure 3.4 Diagram representing COL4A4 including the mutation causing ARHN in the ESS. A
is a model of the gene including the 47 exons and their introns. B is a magnification of the region
encompassing exons 28, 29 and 30; the identified mutation is located in exon 30. C illustrates the
predicted change to the protein sequence of the α4 (IV) collagen chain corresponding to the exon
boundary between exons 29 and 30 (Modified from Davidson et al., 2007).

Genomic Screening of COL4A4 Exon 30
To confirm the mutation found in COL4A4 cDNA, exon 30 was sequenced from
the genomic DNA of 63 ESS. Both ARHN-affected ESS were homozygous for the
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nonsense mutation (thymine). Thirteen of the 25 related ESS and 1 of the unrelated ESS
were identified as carriers of the mutation, having both a cytosine and a thymine at base
2806. All other dogs screened were homozygous at this locus for cytosine (data not
shown).
Discussion
This report documents the occurrence of ARHN in a family of ESS, a breed not
previously reported to be afflicted with this disease. Affected ESS did not harbor the
particular COL4A4 mutation that is known to cause ARHN in ECS; therefore a different
mutation in COL4A4 or a mutation in COL4A3 was anticipated. qRT-PCR was used to
evaluate mRNA transcript quantities of the 2 candidate genes (COL4A3 and COL4A4) as
well as those of COL4A5 in the kidney tissue of affected dogs with the intention of
focusing the search for the mutation preferentially on 1 of the 2 genes. Because transcript
numbers were similarly decreased for both COL4A3 and COL4A4, sequencing of the
coding regions proceeded for both genes. Sequencing of COL4A3 cDNA did not reveal
any mutations, but a nonsense C→T transition was found at base 2806, located in exon
30, of COL4A4. This point mutation changes a codon for a glutamine to a premature stop
codon, and thus is predicted to produce a protein approximately half the normal length
(904 of 1688 amino acids) and lacking the NC1 domain that is required for normal
assembly of α3α4α5(IV) heterotrimers. The data strongly suggest this nucleotide change
is the causative mutation that results in the disease state.
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Figure 3.5 Pedigree of the related ESS. Squares represent male dogs; circles represent female
dogs. Filled shapes indicate affected animals, dark circles within shapes indicate carrier status,
and grey circles within shapes indicate presumed carrier status. Dogs 14 & 15 are the probands.
Dog 27 is unrelated and shares a common ancestor (*) with Dogs 1 & 2 4 or more generations
back. The genotyping results from 1 related dog (†) were inconclusive; however, some of its
progeny in multiple litters were carriers, and the dog thus is presumed to be a carrier. Only
numbered dogs were included in the analysis.

Mutation screening for C2806T in related and unrelated ESS identified 13 carriers
out of 25 related dogs (Figure 3.5) and 1 carrier among 35 unrelated dogs. Detailed
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pedigree analysis identified a common ancestor for the unrelated carrier (dog 27) and the
2 founders of the family (dogs 1 and 2) 4 generations back. The common ancestor
indicates that the mutation is not de novo within the nuclear family in Figure 5, and that
additional carriers within the breed are likely. Given the small number of unrelated dogs
tested in this study, it is not possible to predict the frequency of the mutant allele in the
ESS population. Therefore, a population study to estimate the prevalence of carriers
within the breed is warranted.
A genetic test for the mutant allele would be useful in confirming a diagnosis of
suspected ARHN in an affected ESS. Such a test, however, would be most beneficial to
ESS breeders in identifying carriers, thus aiding in breeding decisions to prevent the
propagation of the disease. Because the prevalence of the mutant allele in the ESS
population is unknown, all dogs in the breeding population might be tested to prevent the
mating of 2 carriers and thus prevent further production of any affected dogs. Offspring
from matings in which 1 parent is a carrier can be tested to select for dogs not carrying
the mutation to be used as future breeding stock. In this way, the mutation can be
removed from the ESS breeding lines in as few as 2 generations.
Finally, the findings in this report, together with the findings in previous reports,
support several general statements about HN. To date, there are 4 different, fully
characterized genetic forms of HN that have been identified. Two forms are X-linked,
affecting Navasota mixed-breed dogs (Cox et al. 2003) and Samoyeds (Zheng et al. 1994),
and each breed possesses a unique mutation in COL4A5. Two forms are autosomal
recessive and are caused by distinct mutations in COL4A4, affecting ECS (Davidson et al.
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2007) and ESS (described here). However, all 4 mutations cause disruptions of gene

translation leading to the synthesis of truncated collagen IV alpha-chains, thus preventing
the assembly of the α3α4α5(IV) network that is crucial for maintenance of GBM
structure and function in the adult kidney. Therefore, the clinical disease produced by all
4 conditions is similar. Affected dogs appear completely healthy as puppies, developing
persistent proteinuria of glomerular origin as their first manifestation of disease (Jansen et
al. 1986; Lees et al. 1998a; Lees et al. 1999). The onset of proteinuria most often is at 4-6

months of age, but can be as early as 2-3 months or as late as 6-8 months of age.
Progression of the disease thereafter is characterized by a period of increasing magnitude
of proteinuria, followed by a period of gradually decreasing glomerular filtration rate and
increasing azotemia, leading to end-stage renal disease, which most often occurs at about
12 months of age, but can occur as early as 6 months or as late as 24 months of age
(Jansen et al. 1986; Lees et al. 1998a; Lees et al. 1998b; Lees et al. 1999). When dogs with

juvenile-onset nephropathies are carefully evaluated, recognition of the clinical features
of HN and exclusion of the clinical features of other conditions generally are sufficient to
raise a high index of suspicion for the diagnosis of HN, but definitive diagnosis of the
condition requires appropriate pathologic evaluations. Nevertheless, light microscopic
examinations alone are not sufficient. The histologic lesions in the kidneys of HNaffected dogs are nonspecific changes that are indicative of glomerular disease but are not
unique to HN. The distinctive morphologic feature of HN, which is the unique
ultrastructural appearance of the GBM, can only be demonstrated by transmission
electron microscopy. Notably, the distinctive ultrastructural GBM change is common to
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all of the fully-characterized forms of HN that have been described, regardless of their
mode of inheritance (Jansen et al. 1986; Lees et al. 1998a; Lees et al. 1999). The type of
pathologic evaluation that can discriminate between the 2 genetic forms of HN is
immunostaining that demonstrates the presence or absence of particular type IV collagen
alpha-chains in the renal or epidermal basement membranes of affected dogs. The pattern
of collagen IV chain expression observed in the ESS in this report is the same as that
observed in ECS and is characteristic of ARHN (Lees et al. 1998b). There is no GBM
labeling for α3(IV) chains, and GBM labeling for α5(IV) is decreased but not completely
absent because α5(IV) chains combine with α6(IV) chains to form a network composed
of α5α5α6(IV) heterotrimers in the GBM of ARHN-affected dogs. This contrasts with
the complete absence of labeling for α3(IV), α4(IV), α5(IV), or α6(IV) chains in XLHNaffected male dogs (Harvey et al. 1998; Lees et al. 1999), which occurs because they cannot
synthesize α5(IV) chains and therefore cannot assemble either α3α4α5(IV) or
α5α5α6(IV) heterotrimers for expression in any basement membrane. Of note, despite
the clinical and pathologic similarities that exist among these inherited nephropathies,
each of the breeds or kindreds of dogs with fully-characterized HN that have been
identified to date have had a different (i.e., unique to that breed or kindred) underlying
causative mutation (Cox et al. 2003; Davidson et al. 2007; Zheng et al. 1994). The practical
consequence of breed-specific mutations is the requirement of a different DNA-based
genetic test in order to identify the mutant allele in each separate dog breed or kindred.
Such an outcome is not surprising because several hundred different causative mutations
have been identified in people with Alport syndrome, and nearly every affected family
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worldwide has its own unique causative mutation in COL4A3, COL4A4, or COL4A5
(Kashtan and Segal. 2011).
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CHAPTER IV
THE FUNCTION OF DOG MODELS IN DEVELOPING GENE THERAPY
STRATEGIES FOR HUMAN HEALTH*

Overview
The domestic dog is of great benefit to humankind, not only through
companionship and working activities cultivated through domestication and selective
breeding, but also as a model for biomedical research. Many single-gene traits have been
well-characterized at the genomic level, and recent advances in whole-genome
association studies will allow for better understanding of complex, multigenic hereditary
diseases. Additionally, the dog serves as an invaluable large animal model for assessment
of novel therapeutic agents. Thus, the dog has filled a crucial step in the translation of
basic research to new treatment regimens for various human diseases. Four wellcharacterized diseases in canine models are discussed as they relate to other animal
model availability, novel therapeutic approach and extrapolation to human gene therapy
trials.

*Portions of this chapter are reprinted with permission from “The Function of Dog
Models in Developing Gene Therapy Strategies for Human Health” by K. Nowend, A.
Starr-Moss and K. Murphy, 2011. Mammalian Genome, 22, 476-485, Copyright 2011 by
Springer Science+Business Media, LLC.
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Introduction
Since sequencing of the canine genome was completed (Lindblad-Toh et al. 2005),
the dog has been widely heralded for its utility as a model for human hereditary diseases
(Galibert and Andre. 2006; Ostrander and Kruglyak. 2000; Ostrander and Wayne. 2005; Parker
and Ostrander. 2005; Parker et al. 2010; Shearin and Ostrander. 2010; Spady and Ostrander.
2008; Sutter and Ostrander. 2004; Tsai et al. 2007) , owing in part to the natural occurrence

of more than 250 hereditary diseases with very similar clinical presentations to analogous
diseases in the human (Anonymous a ). Dogs have been selectively bred, resulting in a
range of phenotypes not observed in any other species. This is most notable in relation to
size: the smallest breeds stand 15cm at the shoulder and weigh less than 3kg, whereas the
largest breeds stand up to 110cm high and can weigh more than 45kg. More than 400
breeds of dog have been developed, each possessing unique behaviors and phenotypes.
Each purebred dog is produced from a closed population: registered dogs must come
from registered parents. However, dog varieties are freely able to interbreed, introducing
diverse genetic backgrounds that can more accurately reflect genetic differences in
human populations. Of additional interest to the many naturally-occurring diseases shared
by human and dog and the phenotypic diversity among breeds is the emotional
investment of owners with affected dogs; to this end, owners, veterinarians, and
researchers alike have a strong commitment to developing preventive and therapeutic
approaches to improve the health of pets.
Importantly, the comparable organ size between large breed dogs and the human
makes the dog useful in clinical trials of new drugs, surgical procedures and gene
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therapy. This latter issue is especially relevant because biological conditions relating to
delivery of gene therapeutic agents can be more closely mimicked in a large animal
model than in the mouse. Also, disease phenotypes in the mouse are not always identical
to those in the human. For example, the mouse model of glycogen storage disease type Ia
does not present with lactic acidosis, a hallmark symptom of the human disease (Kishnani
et al. 1997). Another example is Duchenne muscular dystrophy, which, in the mdx mouse

model does not show the characteristic muscle wasting seen in human DMD (Pastoret and
Sebille. 1995). Most importantly, the immune response to viral vectors that occurs in

mouse models can differ substantially from that observed in the human. These disparate
immune responses necessitate additional trials to evaluate the virulence and
immunoreactivity of vectors in additional model systems (Kishnani et al. 2001). Thus, dogs
fill a critical void between mouse models and human trials for gene therapy.
Many disorders targeted for gene therapy studies are recessive. Therefore, small
amounts of functional wild type product may presumably be sufficient to improve clinical
signs. Preliminary studies in which canine cells were successfully transduced with
retroviral vectors expressing transgenes illustrated the potential for the dog as a
preclinical gene therapy model (Axelrod et al. 1990; Kwok et al. 1986). Shortly thereafter, a
study using adenoviral vector delivery of Factor IX via the portal vein demonstrated
initial success followed by a decrease in gene expression (Kay et al. 1994). Studies such as
these helped establish a foundation for later work. Dogs are currently serving as models
for gene therapy in many disorders, including hematological (Margaritis. 2010; Nichols et
al. 2009), metabolic (Haskins et al. 2006; Koeberl et al. 2009), oncological (Hajitou. 2010),
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ocular (reviewed in (den Hollander et al. 2010)), immunological (leukocyte adhesion
deficiency [(Malech and Hickstein. 2007)], severe combined immunodeficiency [(Sokolic et
al. 2008)]) and musculoskeletal (Duchenne muscular dystrophy [(Nakamura and Takeda.
2011)]) diseases (Table 4.1).

This review discusses four canine hereditary disorders: leukocyte adhesion
deficiency, Duchenne muscular dystrophy, and two retinopathies (Leber’s congenital
amaurosis, and achromatopsia). Each is unique with respect to its reproducibility of
human clinical signs, therapeutic approach, and extrapolation to human gene therapy
trials.
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Table 4.1 Human gene therapy trials based on preclinical trials in canine models
Disease

Initiation
Date
1999

Gaucher's Diseasea
b

Leukocyte adhesion deficiency
Hemophilia A

2001

c

2003
e

Duchenne Muscular Dystrophy

d

2007

Human Clinical
Trial Number
NCT00004294

Type of Study
Phase I

Vector/Molecule
Type
Retrovirus

NCT00023010

Phase I Follow-up

Retrovirus

No number provided

Phase I

Retrovirus

NCT00159250

Phase I/II

Antisense
oligonucleotide

Hemophilia B

f

Leber Congenital Amaurosis, LCA2

g

h

Duchenne Muscular Dystrophy

2007

NCT00515710

Phase I

rAAV2

2007

NCT00516477

Phase I

rAAV2

2009

NCT00844597

Phase I/II

Antisense
oligonucleotide
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Leber Congenital Amaurosis, LCA2

i

2010

NCT01208389

Phase I/II

rAAV2

Leber Congenital Amaurosis, LCA2

j

2011

NCT00999609

Phase III

rAAV2

a

Novelli and Barranger 2001

b

Bauer and Hickstein 2000

c

Powell et al. 2003

d

Year of publication

e

Shimatsu et al. 2003, Kinali et al. 2009

f

Xu et al. 2003, Manno et al. 2006

g

Acland et al. 2001, Acland et al. 2005

h

Shimatsu et al. 2003, Aartsma-Rus et al. 2004

i

Maguire et al. 2008, Amado et al. 2010

j

Acland et al. 2001, Maguire et al. 2008

Leukocyte Adhesion Deficiency-1
Leukocyte adhesion deficiency-1 (LAD-1) is a rare congenital autosomal
recessive disease. The hallmark of LAD-1 is recurrent, potentially life-threatening
bacterial infections (Anderson and Springer. 1987; Crowley et al. 1980). Other symptoms
include progressive periodontal disease, persistent neutrophilia and defective wound
healing, manifesting initially as delayed umbilical cord separation (Crowley et al. 1980).
LAD-1 has a heterogeneous clinical presentation, with both a moderate and a severe form
(Anderson and Springer. 1987). Those children affected by the severe form have a high

incidence of death before the age of two years. With the moderate form, patients can live
into young adulthood and, in rare cases, to middle age (Anderson and Springer. 1987).
LAD-1 is caused by a missense mutation in an integrin gene, ITGB2. This gene
encodes integrin β subunit CD18 that, in normal cells, forms a cell surface adhesion
complex with the α subunit CD11 (Kijas et al. 2000). This protein complex is critical to
the adhesion function of leukocytes and plays a major role in inflammation and immunity
(Arnaout. 1990). Defects in CD18 prevent formation of the CD11/CD18 complex and

impair the ability of leukocytes to adhere to vascular surfaces (Anderson and Springer.
1987; Kijas et al. 2000). With the loss of adhesion, neutrophils are unable to extravasate

from blood vessels and migrate to sites of infection and inflammation, leading to the
chronic life-threatening bacterial infections that characterize this disease. Patient biopsies
from infected tissues show low levels of granulocytes and a marked absence of
neutrophils (Anderson and Springer. 1987; Weisman et al. 1985). Patients also show
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especially high neutrophil counts, indicating that these cells are unable to leave the
bloodstream and migrate to other tissues (Anderson and Springer. 1987).
Currently available treatments for LAD-1 are prophylactic antibiotic therapy and
hematopoietic stem cell transplants (Bauer et al. 2004). Even with regular antibiotic
therapy, patients develop infections that progressively worsen in the complete absence of
neutrophils. Wound infections are very common and often require repeated surgical
intervention to remove infected and necrotic tissue (Bauer et al. 2004). Allogeneic
hematopoietic stem cell transplants have helped somewhat, but still have not been
entirely successful at treating LAD-1 (Bauer et al. 2004). Children receiving these bone
marrow grafts must undergo myeloablative radiation therapy before transplantation,
which can cause lethal complications arising from infections or graft-versus-host disease
(Thomas et al. 1995). The grafts are not always successful in treating the disease and may

require a second graft. Interestingly, stem cell transplantation preceded by nonmyeloablative conditioning has been shown to effectively treat other immunodeficiencies
without the complications seen in myeloablative therapy (Bauer et al. 2004).
There are several animal models of LAD-1. The mouse model is a CD18 null
mutant created to study CD18 function in vivo (Scharffetter-Kochanek et al. 1998).
Although these mice exhibit clinical signs similar to human LAD-1, such as neutrophilia
and neutrophil adhesion defects, the CD18 null mutant is not an ideal model on which to
develop LAD-1 gene therapy. In contrast to mouse, bovine and canine leukocyte
adhesion deficiencies (BLAD and CLAD, respectively) are spontaneously occurring
diseases. BLAD-affected calves show similar clinical signs to human patients (e.g.,

49

defective wound healing, periodontitis, recurrent infections). Blood tests indicate that
neutrophils from these calves have the same adhesion impairment and accumulate within
blood vessels (Kehrli et al. 1992; Shuster et al. 1992; Shuster et al. 1992). The causative
mutation in the bovine model is located within a region of the CD18 gene that is highly
conserved across several species including human. BLAD is considered to be one of the
most common genetic diseases in animal agriculture (Shuster et al. 1992). The annual
economic loss in dairy production as a result of BLAD-affected calves has been
estimated as high as $5,000,000 (Gerardi. 1996). With the persistence of the disease allele
(Meydan et al. 2010; Patel et al. 2007; Powell et al. 1996; Wanner et al. 1998), BLAD

continues to pose significant economic threat to cattle production worldwide.
CLAD is a model of the severe form of LAD-1 and has been described in juvenile
Irish setters (Bauer et al. 2004). The signs of CLAD are identical to those seen in both
bovine and human disease (Bauer et al. 2004; Giger et al. 1987; Renshaw et al. 1975; TrowaldWigh et al. 1992). Neutrophils from affected dogs do not exhibit surface CD11/CD18

complexes and have the same adhesion deficiency as seen in human LAD-1 patients
(Giger et al. 1987; Trowald-Wigh et al. 1992). The same therapies used for LAD-1 are used

to treat CLAD, often with similar results. However, new therapies can be tested in CLAD
for use with LAD-1 patients. The disease phenotype was successfully reversed in
afflicted pups using a non-myeloablative conditioning regimen prior to stem cell
transplantation, leading to the recommendation of this treatment for human LAD-1
patients (Creevy et al. 2003). Although hematopoietic stem cell transplantation methods
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are improving, the treatment does not have a high efficacy and is still prone to
complications.
This led to the development of gene therapy approaches. A gene therapy study
involving two human LAD-1 patients was recently completed in the United States. A
retroviral vector containing CD18 had been administered to the patients during a Phase I
clinical trial in 1999 (FDA investigational new drug study BB-IND-7949), and the
follow-up study was intended to monitor the long-term outcome of the therapy although
results have not yet been released (reviewed in (Bauer and Hickstein. 2000);
ClinicalTrials.gov number NCT00023010). Since this human clinical trial took place,
there have been several ex vivo gene therapy studies assessing efficacy of different viral
vectors in the dog model (Bauer et al. 2008; Bauer et al. 2011; Hunter et al. 2011; Nelson et al.
2010). In ex vivo therapy, target cells are removed from the subject and transduced with a

viral vector containing a transgene. The subject undergoes a conditioning treatment of
total body irradiation and receives an infusion of the autologous transduced cells. In the
case of LAD-1 ex vivo gene therapy, bone marrow is removed from subjects and
hematopoietic progenitor cells are isolated by flow cytometry for transduction and
subsequent infusion.
Studies using lentiviral (LV) and foamy virus vectors containing human
elongation factor 1α and PGK promoters, respectively, to drive expression of CD18 were
unable to reverse the disease phenotype in CLAD dogs (Bauer et al. 2011; Nelson et al.
2010). A recently published study showed that using a specific region of either the human

CD11b or CD18 promoters to drive canine CD18 expression in a self-inactivating (SIN)
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LV vector resulted in CD18 expression on neutrophils. This was sufficient to reverse
CLAD in three of the four dogs receiving gene therapy (Hunter et al. 2011). Use of the SIN
LV vector is thought to reduce the risk of genotoxicity, making this construct a potential
candidate for gene therapy treatment of patients with LAD-1 (Zufferey et al. 1998).
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive degenerative disorder with
an X-linked recessive pattern of transmission. It is the most common and most severe
form of muscular dystrophy (Emery. 2002). The prevalence is approximately 1 in 3500 in
males (Koenig et al. 1988; van Essen et al. 1997). Characteristic symptoms of DMD include
impaired walking and running, muscle weakness, contractures, enlargement of the calf
muscles due to infiltration of adipose tissue, and skeletal muscle degeneration leading to
confinement to a wheelchair before puberty for most patients. Serum creatine kinase
(CK) levels are increased as a by-product of muscle breakdown. Intellectual disability
(IQ < 70) is seen in 20% of affected males (DMD; OMIM #310200). It was common for
death to occur before the age of 25 due to pneumonia with cardiac involvement; however,
as advances in respiratory care are made, patient survival has increased into the early 30s
(Emery. 2002).

DMD is caused by a lack of dystrophin, which is thought to be involved in
cytoskeletal stability (Dalkilic and Kunkel. 2003; Hoffman et al. 1987). Dystrophin, encoded
by DMD, localizes to the muscle cell membrane and binds other membrane proteins at its
C-terminus to form the dystrophin-glycoprotein complex. At the N-terminus, it binds
actin and the cytoskeleton (Campbell. 1995; Oshima et al. 2009). Deleterious mutations in
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DMD cause a loss of dystrophin, and thus instability of the glycoprotein complex and
deterioration of the sarcolemma (Dalkilic and Kunkel. 2003). Between 60-65% of DMD
patients carry a deletion of one or more exons of the DMD gene, most frequently between
exons 45 and 52. Other identified causes of DMD include small insertions or deletions,
point mutations and duplications in the gene (Oshima et al. 2009).
There are no pharmacological agents that effectively manage symptoms. Despite
various reports of glucocorticoid therapies having a short-term slowing effect on progress
of the disease, none of the trials used universal treatment regimens or the same drugs;
thus, no consensus on the long-term effects of treatment has been reached (Emery. 1993).
Surgical intervention is not recommended due to risks from anesthesia (e.g., malignant
hyperthermia) and detrimental effects from bed rest following surgical procedures. No
significant improvement in muscle strength or ambulatory ability is conferred by
prophylactic surgery; however, patients do benefit from surgical correction just prior to
or at the occurrence of contractures (Emery. 1993; Goertzen et al. 1995).
Several animal models of DMD exist, including the mouse and dog. A
spontaneously occurring phenotype, the mdx mouse, was described in an inbred colony of
C57Bl/10 mice characterized by increased serum CK levels and muscle lesions similar to
those seen in DMD patients (Bulfield et al. 1984). The causative mutation in the mdx
mouse was identified as a single base transition in the mouse dystrophin gene causing a
dystrophin deficiency in all but ~1% of skeletal muscle fibers (Sicinski et al. 1989). The
mdx mouse undergoes a continuous cycle of muscle degeneration and regeneration for
most of its life, which is in contrast to human DMD patients whose muscles are replaced
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with accumulations of adipose and connective tissue as they necrose. It is only in aging
mdx mice that regeneration is impaired and adipose accumulations begin (Pastoret and
Sebille. 1995). A second mouse model is the utrophin/dystrophin double knockout (dKO)

mouse. These mice show similar signs of myopathy to mdx mice but the phenotype is
more severe, including cardiomyopathy (Grady et al. 1997; Yue et al. 2006). Although the
dKO mouse more closely resembles DMD, both models are still limited by the size of the
mice and the potential for differential immune reactions to viral vectors.
Golden retrievers, a large breed dog, are affected by an X-linked severe
progressive myopathy called Golden Retriever Muscular Dystrophy (GRMD). Affected
dogs carry a mutation which causes faulty RNA processing of dystrophin, skipping exon
7 and transcribing exon 8 out of frame (Sharp et al. 1992). Characteristic signs of the
disease are gait abnormalities, gradual skeletal muscle atrophy and increased serum CK
levels (Cooper et al. 1988; Kornegay et al. 1988). Muscle contractures cause limb
deformities, and much like DMD, respiratory failure and cardiomyopathy are common
(Nguyen et al. 2002; Sharp et al. 1992). Distinctive signs of GRMD (and both canine models

discussed below) are macroglossia and dysphagia (Kornegay et al. 1988; Shimatsu et al.
2003; Walmsley et al. 2010). The skeletal and cardiac signs of GRMD more closely

resemble DMD than the mdx model. This, along with the larger body size of the golden
retriever compared to the mouse, makes it a compelling animal model in the study of
DMD (Nakamura and Takeda. 2011).
There are two additional canine models of DMD. The canine X-linked muscular
dystrophy in Japan (CXMDJ) model was developed in the beagle, a medium-sized breed,
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from a GRMD-affected golden retriever and carries the same mutation. Briefly, an
unaffected female beagle was crossed with a male GRMD-affected golden retriever.
Female offspring from this mating carrying the mutation were mated with normal male
beagles to establish a breeding colony (Shimatsu et al. 2003). This model manifests the
same clinical signs in a milder phenotype than the GRMD (Shimatsu et al. 2003). Recently,
these signs were described in a toy breed, the Cavalier King Charles Spaniel (CKCSMD). This breed presents with a severe spontaneous phenotype analogous to human
DMD caused by a deletion of exon 50 of the dystrophin gene. Deletions in this exon are
the most common causative mutations in human patients (Walmsley et al. 2010).
Gene therapy studies have been carried out in mouse and dog models of DMD
using a shortened functional form of dystrophin which can be incorporated into
recombinant adeno-associated viral (rAAV) vectors. Expression of both micro- and minidystrophin has been demonstrated to recover muscle function in the mdx and dKO mouse
models (Gregorevic et al. 2008; Wang et al. 2009; Watchko et al. 2002; Yoshimura et al. 2004).
In a recent study, both ex vivo gene therapy and electrotransfer of the plasmid encoding
the microdystrophin were used to successfully express the transgene in both the mdx
mouse model and the GRMD dog model (Pichavant et al. 2010). After administration of a
rAAV9 human mini-dystrophin vector to neonatal dogs lacking dystrophin, expression of
the construct was seen throughout the skeletal muscles. However, an immune reaction to
the treatment was also noted, possibly due to the promoter or a human protein in canine
muscle (Kornegay et al. 2010). Intravenous injection of a rAAV8 microdystrophin to
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CXMDJ dogs was able to induce widespread expression of the transgene for the eightweek duration of the study (Ohshima et al. 2008).
Exon-skipping therapy using antisense oligonucleotides (AO) is another form of
gene therapy being studied for DMD (Kinali et al. 2009; Saito et al. 2010). As discussed
above, many patients have a mutation in a splice site which, during transcription, causes
deletion of an exon and a frameshift mutation (Oshima et al. 2009). The goal of exon
skipping therapy is to recover a shortened functional protein from a gene harboring a
mutation. By binding AO to the region containing the mutation, the ribosome is able to
bypass the bound region and resume transcription further down the gene (van Deutekom.
2005).

Successful expression of functional dystrophin following skipping of exon 23 has
been shown in the mdx mouse (Fletcher et al. 2006; Jearawiriyapaisarn et al. 2008; Lu et al.
2005). Recent work demonstrates that a multiple-exon skipping technique (exons 6-8)

using injection of morpholinos, a type of AO, results in widespread expression of
functional shortened dystrophin in the CXMDJ model (Yokota et al. 2009). Using this
same technique in vitro, similar dystrophin recovery was achieved in fibroblasts
harvested from a human DMD patient with an exon 7 deletion (Saito et al. 2010). AOmediated skipping of exon 51 in the CKCS-MD model successfully restored dystrophin
expression in skeletal muscles. The CKCS-MD will be a valuable contribution to
preclinical trials for DMD as the majority of human deletions are between exons 45 and
52 (Aartsma-Rus et al. 2004; Walmsley et al. 2010). Phase I/II clinical trials for this therapy
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in human patients are currently underway in the UK ((Kinali et al. 2009);
ClinicalTrials.gov NCT00844597).
Leber’s Congenital Amaurosis
Leber’s congenital amaurosis (LCA) is a group of autosomal recessive
degenerative retinopathies causing bilateral partial or total blindness in infancy (LCA;
OMIM #204000). Characteristic symptoms of LCA are nystagmus, eye poking behavior
and severe visual impairment with little or no light perception. Signals from
electroretinogram (ERG) testing are undetectable (Perrault et al. 1999). Although the
photoreceptors lining the fundus appear normal initially, an abnormal appearance (e.g.,
salt-and-pepper pigmentation, atrophy of the retinal pigment epithelium) progressively
develops over several years. LCA has a prevalence of approximately 1/81,000 (Stone.
2007).

There are 14 subtypes of LCA, designated LCA1-LCA14, which are
differentiated by the genes harboring the causative mutations (LCA; OMIM #204000).
This review will focus on LCA2, caused by mutations in RPE65, as this subtype is one of
the most well-understood (Cai et al. 2009; den Hollander et al. 2008; Marlhens et al. 1997).
Marlhens and colleagues identified two distinct mutations in RPE65 in two siblings with
LCA2. The patients were compound heterozygotes for both mutations, inheriting one
from each parent, causing two distinct truncated proteins (Marlhens et al. 1997). The gene
product, RPE65, localizes to the retinal pigment epithelium and is involved in
regeneration of visual pigment in photoreceptors. Defective or absent RPE65 impairs
phototransduction and can cause partial or complete blindness (Nicoletti et al. 1995).
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The briard, a large breed dog, is afflicted by an inherited congenital retinal
dystrophy caused by a four nucleotide deletion in RPE65 (Veske et al. 1999). The
causative mutation in briards is not the same mutation found in humans affected by LCA.
However, both canine and human mutations result in a complete loss of RPE65, and the
briard is a canine model of LCA2 (Acland et al. 2001). Similar to human patients, briards
have night blindness, various degrees of impaired vision in daylight and undetectable or
abnormal ERG readings (Narfstrom et al. 1989; Veske et al. 1999). Nystagmus is present in
affected puppies; although the dogs outgrow this aspect of the disorder, excitement can
induce a recurrence (Aguirre et al. 1998). Signs of the disorder were initially thought to be
static, but close observation of affected dogs revealed a progressive component to the
disease (Aguirre et al. 1998; Narfstrom et al. 1989).
A RPE65-/- mouse was created during the same time period the briard was
initially characterized. While the mouse model is of importance to understanding the
function of RPE65 in vivo, there are clear differences between the phenotypes of the
RPE65-/- mice and human LCA2 patients. Human patients have rod and cone
dysfunction, whereas the knockout mice retain functional cones (Redmond et al. 1998).
Because of this difference, RPE65-deficient mice are not the optimal system in which to
validate new therapies for LCA2.
In 2001, a proof-of-concept gene therapy study was performed in affected briards.
Recombinant AAV vector expressing wild-type RPE65 delivered intra-ocularly to
RPE65-/- dogs was able to restore vision. In each dog, the vector was delivered
subretinally to only one eye (Acland et al. 2001). A Phase I/II clinical trial delivering the
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same vector construct unilaterally to three human LCA2 patients soon followed
(ClinicalTrials.gov number NCT00516477). This treatment resulted in improvements in
visual acuity and pupillary reflex that lasted at least the six months of follow-up during
the study (Maguire et al. 2008). Based on these preliminary results, a Phase III clinical trial
was scheduled to begin in January 2011 with 12 patients (ClinicalTrials.gov number
NCT00999609).
Because both of these studies had only examined viral delivery to one eye, a
recent study investigated the safety of subretinal readministration of rAAV vectors to the
same animal in the contralateral eye (Amado et al. 2010). RPE65-containing AAV was
administered to the contralateral eye of RPE65-/- dogs previously treated with the vector
constructs to determine the safety and efficacy of a second treatment. Not only did the
gene therapy restore vision to the treated eye, but no adverse reactions were seen as a
consequence of a second administration of the viral vector (Amado et al. 2010). Phase I/II
clinical trials to examine the safety and efficacy of readministration to the contralateral
eye in human patients are currently ongoing (ClinicalTrials.gov number NCT01208389).
Achromatopsia
Another form of hereditary retinopathy affecting dogs and humans is
achromatopsia. The term achromatopsia can refer to both complete and incomplete forms
of the disorder, as well as acquired and congenital forms. This review addresses complete
congenital achromatopsia, an autosomal recessive cone dysfunction sometimes referred
to as rod monochromacy (Michaelides et al. 2004). Approximately 1 in 30,000 people are
affected, with initial diagnosis made during infancy. Symptoms include photophobia,
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impaired visual acuity and nystagmus. Electroretinogram (ERG) readings indicate an
absence of cone function yet normal rod function. Nystagmus, and in some cases, acuity,
improve during development; however, color vision is lacking in human patients
(Michaelides et al. 2004; Michaelides et al. 2006). The disorder does not appear to have a

progressive component, remaining stable throughout the patients’ lives.
Achromatopsia is genetically heterogeneous; mutations in four distinct genes
involved in the cone phototransduction cascade are associated with the disorder. GNAT2
encodes the α subunit of cone transducin (Gropp et al. 1996). Mutations in this gene are
considered to be ‘leaky’ and cause a less severe phenotype because a small amount of
correctly spliced mRNA transcripts are produced (Rosenberg et al. 2004). Mutations in the
genes encoding either the α subunit of cone phosphodiesterase, PDE6C (Thiadens et al.
2009), or the α and β subunits of the cone photoreceptor-specific cyclic nucleotide-gated

(CNG) channel, CNGA3 and CNGB3 respectively, cause the full phenotype of complete
achromatopsia (Ding et al. 2009; Kohl et al. 2000; Milunsky et al. 1999; Wissinger et al. 1998;
Wiszniewski et al. 2007).

The CNG channel is localized to the cone photoreceptor plasma membrane. In
darkness, the channel is open and the cells are in a state of constant depolarization. Light
activates the phototransduction cascade, causing the channel to close and hyperpolarize
the photoreceptor cell. The subunits of the channel form heterotetramers (two α subunits
and two β subunits) and are thought to be functionally distinct: the α subunit conducts
ionic activity, and the β subunit functions as a modulator (Gerstner et al. 2000). More than
50% of achromatopsia cases are caused by mutations in CNGB3. Thr383fsx is the most
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common mutation, accounting for over 70% of mutant CNGB3 alleles. The frameshift
caused by this mutation prematurely truncates the protein; thus, no functional protein is
produced, preventing the formation of CNGA3/CNGB3 heterotetramers (Kohl et al. 2005;
Wiszniewski et al. 2007).

Canine cone degeneration (cd) has been established as a valid animal model of
achromatopsia caused by CNGB3 mutations. Two separate phenotypes have been
identified in the German Shorthaired Pointer (GSP) and the Alaskan Malamute-derived
(AMD); two distinct mutations segregate with each phenotype. GSPs experience day
blindness caused by a missense mutation in CNGB3. A deletion of at least 140 kb in the
same gene causes cd in the AMD lineage (Sidjanin et al. 2002). Affected dogs have clinical
signs very much like those seen in the human: impaired visual acuity, photophobia and
nystagmus beginning around 8 to 12 weeks of age (Aguirre and Rubin. 1974; Rubin et al.
1967). Although cone-specific ERG signals are detectable at three to six weeks of age,

adult dog retinas completely lack cone function and ERG signals are undetectable
(Aguirre and Rubin. 1975).

Gene therapy for achromatopsia is being developed for the dog cd models
(Komaromy et al. 2008; Komaromy et al. 2010). Initial work to determine the optimal

promoter to drive gene expression of a green fluorescent protein (GFP) in a recombinant
AAV5 vector showed that the red cone opsin promoter confers a higher level of
specificity and greater expression levels than the human S-opsin promoter (Komaromy et
al. 2008). Subsequent studies showed that unilateral subretinal injection of human CNGB3

cDNA driven by the red-cone opsin promoter in a rAAV5 vector was able to restore cone
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function in the treated eye in both phenotypes. Rescue of function was measured by both
cone-specific ERG and vision behavior under bright light conditions. Because CNGB3
mutations are the predominant cause of achromatopsia, this treatment could also offer a
promising therapy to human patients (Komaromy et al. 2010).
Summary
Characterization of dog models of disease has provided a strong foundation for
understanding the functional significance of hereditary disease. In some cases, dog
models have preceded mouse models and in others, dog models more accurately reflect
the human disease progression, clinical signs, and response to treatment than the mouse.
While only a handful of diseases are being actively investigated in advanced (phase
III/IV) human gene therapy trials, (e.g., Leber’s congenital amaurosis), recent studies in
the dog offer great promise of potential therapies for lysosomal storage diseases,
including glycogen storage disease Ia (Koeberl et al. 2008; Weinstein et al. 2010), Hurler
syndrome (Ellinwood et al. 2011; Traas et al. 2007), Sly syndrome (Mango et al. 2004; Wang
et al. 2006; Xu et al. 2002), and Sanfilippo syndrome (Ellinwood et al. 2011);

coagulopathies, including hemophilia A and B (reviewed in (Margaritis. 2010));
retinopathies such as LCA6 (Lheriteau et al. 2009); and cancers, including astrocytoma
(Pluhar et al. 2010), sarcoma (Finocchiaro et al. 2011), and general neoplasms (Hajitou. 2010;
Reed et al. 2010; Thamm et al. 2010).

By discussing the role of the dog in gene therapy trials, we hope to highlight the
unique attributes of the dog, not only as a model for understanding simple traits, but also
as a critical member of the therapy development pipeline for human health. While the
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importance of mouse models cannot be overstated, data being generated from current,
basic research in additional model organisms will enhance the knowledge base for
translational medicine to draw upon for future therapies.
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CHAPTER V
SUMMARY

The 7.5x canine genome assembly was, and is, an indispensable resource for
study of canine genetics. However, despite substantial work by a number of laboratories
to improve the reference genome, gaps in coverage contain 1% of the euchromatic
genome. Such regions likely contain GC-rich promoter regions as well as repetitive
sequences. Amplification and sequencing through promoters and 5′ regions of genes is
very difficult because regions with high GC content form secondary structures that stall
DNA polymerase.
A gap in CFA 25 between COL4A3 and COL4A4 has prevented identification of
the full sequences of COL4A3 and the predicted promoter. Mutations in each of these
genes are known to cause HN. Using degenerate PCR primers, we were able to amplify
and sequence 39 bases of exon 1 and the 32 bases of exon 2 of COL4A3. Determining the
sequence of the promoter and 5′ regions of COL4A3 and COL4A4 contributes to coverage
of the canine genome, and may be critical for identifying novel mutations associated with
HN.
Although gaps in sequence coverage only encompass a small percentage of the
canine genome, efforts by our lab and others focused on filling in these regions are
necessary. As revealed by this work, gaps may harbor promoters and genes associated
with severe disease phenotypes (e.g., autosomal dominant HN). There exists an urgent

64

need to identify the genes and/or regulatory elements contained within these regions to
uncover novel mutations causative for such diseases.
Recently a 50x coverage assembly of the collie genome was generated by our
laboratory using the Illumina next generation sequencing platform. According to our
assembly parameters, only paired-end reads aligning at both ends to the canine reference
genome sequence were incorporated into the assembly. Discordant reads were not
included; however, there may be a number of discordant reads for which one end may
align to sequences flanking the gap regions. These may be used to carry out chromosome
walking in order to span the gap. Even if this provides only single coverage of the gap
region, the resulting sequence will still be very useful (Kirkness et al. 2003). If this
successfully bridges the gap located on CFA25 between COL4A3 and COL4A4,
chromosome walking may be equally useful in sequencing through other regions missing
from the canine reference genome.
Little is known about mechanism by which type IV collagen gene bifunctional
promoters drive expression of gene pairs, and access to the full sequence of the promoter
and both genes will allow for cloning and functional characterization of the promoter.
Identification of binding sites within the promoter as well as promoter-proximal elements
found in either gene could provide information about type IV collagen biochemical
pathways and mechanisms of individual or tandem gene expression. Recognition and
characterization of promoter-proximal elements could potentially assist in our
understanding of the variability in disease severity observed in patients with AS resulting
from different mutations.
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HN is a devastating disease affecting several breeds of dog. Dogs affected by Xlinked and autosomal recessive HN usually reach ESRD by 12 months of age. We
identified a novel COL4A4 mutation that segregates with the disease phenotype in a
family of ARHN-affected ESS. Prior to diagnosis of ARHN in the probands, the disease
was not previously known to affect the ESS. As with other traits inherited through
autosomal recessive transmission, it is difficult to identify carriers until affected offspring
are produced. The symptoms of HN do not appear until ESRD and are identical to those
seen in other forms of acute renal disease. It is impossible to diagnose HN without
confirmation by immunostaining and transmission electron microscopy of renal biopsy
samples. Therefore, the disease may not be correctly diagnosed in dogs presenting with
signs of ESRD.
The disease allele was identified by a simple test based on PCR amplification and
sequencing of the exon containing the mutation. The screening test will be highly
beneficial because it will identify dogs that carry the deleterious allele and such dogs can
be removed from breeding lines. Through increased awareness of HN in the ESS by the
veterinary community, along with identification of carriers and careful breeding
practices, the mutation can be eradicated from the breed in as few as three generations.
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Appendix A
Methods for Amplifying and Sequencing GC-Rich Templates

Efforts to sequence across the gap on CFA 25 between COL4A3 and COL4A4
required many modifications to amplification protocols and cycling parameters. In order
to assist future endeavors to sequence GC-rich regions, the following table provides
names and suppliers of the reagents used as well as the final concentration or ranges of
concentration of the reagents in each reaction.

Table A-1. Reagents used to optimize PCR for amplification of GC-rich templates
Reagent Name
Supplier
Concentration
PCR additives
Betaine
Sigma-Aldrich
0.5-2.0 M
Dimethyl sulfoxide (DMSO)
Fisher Scientific
5-11%
7-deaza-dGTP
New England Biolabs
50 µM
Bovine serum albumin (BSA)
New England Biolabs
400 µg/ml
Magnesium source
Magnesium chloride (MgCl2)
Magnesium sulfate (MgSO4)

Fisher Scientific
Invitrogen

1.0-4.0 mM
4.0 mM

Polymerases
Taq DNA polymerase
Advantage2 GC polymerase
Phire HotStart II polymerase

Fisher Scientific
Clontech
Finnzymes

1.25-2.0 U
1X
1 µl
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Appendix B
A missense mutation in the 20s proteasome β2 subunit of great danes having
harlequin coat patterning*

Overview
Harlequin is a pigmentary trait of the domestic dog that is controlled by two
autosomal loci: the melanosomal gene, SILV, and a modifier gene, harlequin (H),
previously localized to chromosome 9. Heterozygosity for both a retrotransposon
insertion in SILV and a mutation in H causes a pattern of black patches on a white
background. Homozygosity for H is embryonic lethal. Fine mapping of the harlequin
locus revealed a 25 kb interval wherein all harlequin Great Danes are heterozygous for a
common haplotype. This region contains one gene, PSMB7, which encodes the β2
catalytic subunit of the proteasome. Sequence analysis identified a coding variant in exon
2 that segregates with harlequin patterning. The substitution predicts the replacement of a
highly conserved valine with a glycine. Described herein is the identification of a
naturally-occurring mutation of the ubiquitin proteasome system that is associated with a
discernable phenotype of dogs.

*Reprinted with permission from “A missense mutation in the 20S proteasome β2
subunit of great danes having harlequin coat patterning” by L.A. Clark*, K.L. Tsai, A.N.
Starr, K. L. Nowend and K.E. Murphy, 2011. Genomics, 97, 244-248, Copyright 2011 by
Elsevier.
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1. Introduction
The coat of the domestic dog is diverse in color, pattern, length, and texture. To
date, at least 10 genes governing canine coat variation have been identified (Cadieu et al.
2009; Housley and Venta. 2006; Schmutz and Berryere. 2007), but many distinguishing traits

have yet to be described at the genetic level. Harlequin is a coat pattern of distinctive
dark spots on a white background (Fig. B-1A). Although most coat variation in dogs is
controlled by a single locus, harlequin is a genetically complex coat pattern, resulting
from heterozygous mutations at two loci: merle (M) and harlequin (H) (O'Sullivan and
Robinson. 1988; Sponenberg. 1985). By itself, the Mm genotype causes a more colorful

pattern, termed merle, characterized by dark spots on a dilute background (Fig. B-1B). H
is a dominant modifier of M that removes the dilute pigment and increases the size of the
fully-pigmented regions. H has no visible phenotypic effect in mm (wild-type) dogs (Fig.
B-1C); therefore, merle is the only phenotype that unequivocally indicates an hh
genotype. The base coat color of harlequin and merle dogs is controlled by separate loci
(Schmutz and Berryere. 2007).
We previously determined that a retrotransposon insertion near an exon boundary
of the melanosomal gene SILV (also known as Pmel17) is responsible for the merle coat
pattern (Clark et al. 2006). SILV encodes the fibrillar array on which melanin is deposited
in eumelanosomes and is strongly expressed during embryonic development (Baxter and
Pavan. 2003; Theos et al. 2005). A cryptic splice acceptor site within the insertion causes

retrotransposon sequence to be incorporated into SILV mRNA in merle dogs(Clark et al.
2008).Variability in the number of di-nucleotide repeats within the insertion results in
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Figure B-1. Phenotypes resulting from genetic variations at the M and H loci in the Great
Dane. (A) A classic harlequin with black patches on a white background. (B) A merle,
characterized by black patches on a dilute background. (C) A non-merle harlequin,
phenotypically indistinguishable from mmhh.

multiple mutant SILV transcripts (Clark et al. 2008). Truncation of the poly-A tail of the
retrotransposon permits proper splicing and normal pigmentation (Clark et al. 2006). The
random dark spots characteristic of the merle and harlequin patterns may be the result of
somatic replication errors during development that truncate the poly-A tail (Clark et al.
2008).
Harlequin is most common in the Great Dane breed, although reports of the
pattern appearing spontaneously in merle populations of other breeds are not uncommon.
Comprehensive studies of Great Dane breeding records show that harlequins do not breed
true, indicating that they are heterozygous for H, and that the HH genotype is not viable
(O'Sullivan and Robinson. 1988; Sponenberg. 1985). Because harlequin-to-harlequin matings

are not associated with stillbirths, HH likely causes lethality early in embryogenesis. In
order to map the H locus, six small, multigenerational pedigrees of harlequin and merle
Great Danes were previously assembled for use in a genome-wide scan for linkage.
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Significant LOD scores were detected for microsatellite markers on chromosome 9
(maximum LOD = 4.07) and recombination events delimited the H locus to a 3.2 Mb
region (Clark et al. 2008)(Clark et al. 2008). The region harbors 20 genes, none of which is
known to have a role in pigmentation.
In the dog, interbreed linkage disequilibrium (LD) is short and is therefore the
preferred method for high-resolution mapping of identical-by-decent mutations that are
common to several breeds (Karlsson et al. 2007). Nevertheless, the selection of genetically
diverse individuals can allow for the use of LD in fine-mapping studies of phenotypes
that are found predominantly in a single breed (Bannasch et al. 2008; Kukekova et al. 2009).
In the present study, meiotic recombination events and LD mapping using unrelated
harlequin dogs define the H locus in the Great Dane breed. Harlequin Great Danes are
obligate heterozygotes; therefore, a critical interval was determined by identifying the
region in which only one haplotype is in LD with the phenotype. Sequence analysis of the
only gene in the region, PSMB7, reveals a single coding mutation that is heterozygous in
all phenotypic harlequin Great Danes. We present here fine mapping of the H locus and
analysis of a candidate causal mutation in PSMB7.
2. Materials and Methods
2.1. Sample collection
DNA samples isolated from whole blood or buccal cells from Great Danes and
other pure bred dogs were available from previous and unrelated studies. Private owners
of Great Danes submitted buccal cells from kindreds segregating harlequin and merle,
and from unrelated dogs (no common grandparents) of various coat patterns and colors in
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the general population. Genomic DNA was isolated using the Gentra Puregene Blood Kit
(Qiagen, Valencia, CA, USA). Three nuclear families collected were comprised of 16
harlequins, 13 merles, and 4 solid Great Danes.
Skin tissue was submitted from five harlequin and three merle Great Dane
puppies. Samples were acquired from ear tissues removed during routine cropping
procedures and stored in RNA later® (Ambion, Austin, TX, USA) at -20°C. Total RNA
was isolated using the RNA STAT-60TM (Tel-Test, Inc., Friendswood, TX, USA)
protocol. RNA was treated with DNA-free DNase (Ambion). All samples were collected
following protocols approved by the Clemson University Institutional Review Board
(#IBC2008-17).
2.2. Marker identification and genotyping
Microsatellites located within the candidate region on chromosome 9 were
identified using the dog genome assembly (CanFam 2.0). Forward primers were
fluorescently labeled with 6FAM (Suppl. Table 1). PCR amplification of all
microsatellite markers was carried out as previously described (Clark et al. 2004). Products
were resolved on an ABI Prism 3730 Genetic Analyzer (Applied Biosystems, Carlsbad,
CA, USA) with the GeneScan 500 LIZ internal size standard (Applied Biosystems).
Genotypes were determined using Genemapper® Software v3.5 (Applied Biosystems).
Eighteen SNPs were selected from CanFam 2.0 and seven SNPs and five indels
were identified during sequencing. Primer sequences are listed in Supplementary Table 2.
PCR amplicons were analyzed by electrophoresis on agarose gels. Products were purified
via gel extraction (QIAEX II Gel Extraction Kit, Qiagen) or by adding 0.5 units
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Exonuclease I (New England Biolabs, Itswich, MA, USA) and 0.25 units of shrimp
alkaline phosphatase (Promega, Madison, WI, USA) and incubating for 30 min at 37°C
followed by 20 min at 80°C. Nucleotide sequencing was accomplished using the Big Dye
Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems). Products were
purified using Spin-50 mini-columns with water (BioMax, Inc., Arnold, MD, USA) and
resolved on an ABI Prism 3730 Genetic Analyzer (Applied Biosystems).
2.3. Analysis of PSMB7
All primer sequences used in the amplification of PSMB7 are shown in
Supplementary Table 3. Amplification of the promoter region, all exons, and splice sites
of PSMB7 was carried out from genomic DNA. Primers were also designed to capture
complete cDNA sequence. cDNA synthesis from RNAs was accomplished using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For RACE,
cDNA was synthesized using the SMARTTM RACE cDNA Amplification Kit (Clontech,
Mountainview, CA, USA), and product amplification was achieved using the Advantage
2 PCR Kit (Clontech). All sequences were aligned using CLUSTAL W
(www.ebi.ac.uk/clustalw).
Primers for quantitative RT-PCR (qRT-PCR) were tested to ensure amplification
of a single PCR product. Reactions were prepared according to the iQ SYBR® Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA) protocol and performed using a
Bio-Rad MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad Laboratories).
All reactions were carried out in triplicate, and quantification of gene expression was
achieved by normalization against GAPDH. The comparative Ct method, also known as
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the 2-∆∆Ct method, where ∆∆Ct = ∆Ct,sample - ∆Ct, reference, was used to report the differential
gene expression.
3. Results
3.1. Fine mapping of the H locus
Genotype data for four microsatellite markers (GAAA1, FH2885, GAAA2, and
Ren287G01) that define or are within the H locus (Clark et al. 2008) were generated for
newly acquired families of harlequin and merle Great Danes. In one family, a
recombination event between the H locus and FH2885 was detected, narrowing the H
locus to a 2.6 Mb region. To further refine this region, four new microsatellites between
FH2885 and Ren287G01 were identified and genotyped for families with informative
recombination events. Three markers centromeric to the H locus were genotyped in a
family comprised of six harlequin and two merle dogs. One telomeric marker was
genotyped in three families, collectively comprised of 13 harlequin, 9 merle, and 4 solid
Great Danes. Two recombinant chromosomes (Suppl. Figures 1 and 2) delimited H to a
1.23 Mb region on chromosome 9, defined by the CT/CA and CA microsatellites (Fig. B2A). This region contains 11 genes.
Nine unrelated Great Danes (8 harlequins and 1 merle) were genotyped for 30
SNPs and indels across the 1.23 Mb H interval. A 226 kb harlequin haplotype was
identified and defined by SNPs 61.827 and 62.053. This region contains three genes:
GPR144, PSMB7, and NEK6 (Fig. B-2B). We could not further narrow the critical
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Figure B-2. Genetic mapping of the H locus in the Great Dane. (A) Physical map of
chromosome 9 showing the location of microsatellite and SNP markers. Microsatellite name or
repeat sequence is shown below the line and directly above is the position in Mb. H was
previously mapped to a 3.28 Mb region. Recombination mapping using microsatellites refined the
locus to 1.23 Mb. Association mapping using SNPs and indels revealed a 226 kb harlequin
haplotype. (B) Genotypes for markers defining and within the 226 kb harlequin haplotype block
are represented for the 8 harlequin and 1 merle dogs used to fine map H. Homozygosity is
denoted by black for the major allele and white for the minor allele. Grey boxes indicate
heterozygosity. The names of the three genes in the haplotype region and their locations relative
to the markers are shown below the genotypes. The 25 kb block of heterozygosity in harlequin
dogs is marked. The coding SNP in PSMB7 is indicated by an asterisk.
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interval using conventional homozygosity mapping because HH is early embryonic lethal
and all harlequin dogs are obligate heterozygotes. Alternatively, we identified a single 25
kb haplotype block wherein all harlequin dogs are heterozygous. A homozygous interval
in the merle dog (hh) overlaps this region. This homozygous merle haplotype was used to
determine the wild-type chromosome of harlequins. The alleles of the wild-type
haplotype are in agreement with the canine reference sequence, generated from a boxer
(Lindblad-Toh et al. 2005). Therefore, we infer that the non-wild-type haplotype identified

in harlequin dogs is found on the harlequin chromosome. The 25 kb region of
heterozygosity contains the promoter region and first 4 exons of PSMB7.
3.2. Sequence and expression analysis of PSMB7
Sequence data from four Great Danes (three harlequin and one merle) were
generated for the promoter region, all eight exons, splice sites, and flanking intronic
regions of PSMB7. Only two heterozygous polymorphisms were present in all three
harlequin dogs and absent from the merle dog: a T to G transversion in exon 2, and one
intronic SNP. The intronic SNP, located 50 bp downstream from the coding SNP, was
detected in two merle Australian shepherds and thus eliminated as a candidate mutation.
Additional sequence data covering 92% of the 25 kb heterozygous block,
including 21.5 kb 5' of PSMB7 and introns 1 through 3, were generated for a harlequin
dog (Suppl. Figure 3). Thirty-six of 113 polymorphisms identified were heterozygous
(Suppl. Table 4), and six of these were previously described in other breeds. The 30
remaining variants fell into three groups: 19 SNPs, 6 indels, and 5 repeat polymorphisms.
Twenty-nine variants were considered unlikely to affect transcriptional regulation or
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expression of PSMB7 based on Dog/Human/Mouse/Rat Multiz conservation scores
obtained from the UCSC dog genome browser (Fujita et al. 2011). An insertion (16 bp
segmental duplication) genotyped in our haplotype analysis occurred in a region showing
cross-species conservation but was heterozygous in a merle dog and thus eliminated as a
candidate.
Quantitative RT-PCR was used to evaluate PSMB7 mRNA levels in skin from
five harlequin (MmHh) and three merle (Mmhh) Great Danes. No significant difference
in PSMB7 expression was detected (-1.17 fold change in harlequin dogs). Sequencing of
the complete cDNA for PSMB7 from a harlequin dog confirmed that both wild-type and
mutant alleles are transcribed and that no other mutations are present (GenBank accession
nos. GU305912 and GU305913).
3.3. Analysis of the c.146T>G mutation
The variant, c.146T>G, was analyzed in 247 Great Danes and 104 dogs from
other breeds. All harlequin Great Danes (n = 102) were heterozygous for the SNP and all
merle dogs (n = 48) were homozygous wild-type. Fifty-nine percent of black (mm) Great
Danes (n = 71) were heterozygous for the variant. Non-merle dogs (n = 81) representing
43 different pure breeds do not have the allele. None of the 351 dogs genotyped was
homozygous for the c.146T>G mutation (Table B-1). Two merle Great Danes with white
markings did not have the variant or share the harlequin haplotype.
The c.146T>G mutation occurs in the second exon, causing a valine to be
replaced with a glycine at the 49th residue. To assess the significance of this mutation,
we utilized PANTHER, a web service that predicts the functional consequences of amino
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acid substitutions. PANTHER assigned the p.Val49Gly variant a score of -6.86 (results <
-3.0 are considered functionally significant with more negative results indicating a higher
likelihood that the substitution will impair protein function) and a 0.98 probability of
being deleterious (Thomas et al. 2003; Thomas et al. 2006). In contrast, a p.Val49Ile variant
observed in other species was predicted to be neutral, with a score of -2.80 (Smyth and
Belote. 1999).
Table B-1 Distribution of genotypes at nucleotide 146 of PSMB7 among 247 Great Danes and
104 dogs from other breeds
% Genotype
T/G

Phenotype
Great Dane cases (M-Hh)
Harlequin (Mm)
White (MM)

n

T/T

G/G

88
14

0
0

100
100

0
0

Merle controls (M-hh)
Great Danes
10 other breeds

25
23

100
100

0
0

0
0

Non-merles (mm-h)
Great Danes
Black
Fawn
Brindle
Blue
43 other breeds

71
30
11
8
81

41
97
91
88
100

59
3
9
12
0

0
0
0
0
0

4. Discussion
Harlequin, a bigenic coat pattern exclusively selected for in the Great Dane breed,
is caused by mutations in SILV and H. SILV is known to have an integral role in the
development of melanocytes and harbors mutations that cause pigmentary defects in
several species (Brunberg et al. 2006; Kerje et al. 2004; Kuhn and Weikard. 2007; Kwon et al.
1995; Schonthaler et al. 2005). Linkage mapping for the Great Dane unexpectedly placed H
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within a segment of chromosome 9 that lacked genes known to influence pigmentation.
Haplotype analysis and heterozygosity mapping indicated that H is located in a 25 kb
region containing partial coding sequence for only one gene: PSMB7, a component of the
proteasome. All phenotypic harlequin Great Danes harbor a heterozygous SNP
(c.146T>G) in exon 2 of PSMB7. The variant is absent from all merle dogs and, although
present in nearly 60% of our Great Dane population, is never observed in a homozygous
state. The mutation was not detected in any other breeds tested herein, including ten
breeds having merle coat patterning. Based on these data, we propose that an alteration of
the proteasome is the functional basis for the harlequin pattern of the Great Dane. Direct
mutation of the proteasome has not previously been associated with pigmentary traits;
however, the abnormal processing and/or trafficking of mutant proteins by the ubiquitin
proteasome system is hypothesized to play a role in hypopigmentary diseases such as
oculocutaneous albinism (Ando et al. 2009).
Protein degradation is an essential part of many biological processes, including
cell cycle progression, DNA repair, apoptosis, and stress response. The ubiquitin
proteasome system represents the primary pathway for regulated protein degradation
(Tanaka. 2009). Proteins scheduled for turnover and those damaged by gene mutations or

misfolding undergo a post-translational modification in which ubiquitin monomers are
covalently attached to lysine residues in the target protein, thereby labeling them for
degradation (Ravid and Hochstrasser. 2008). The 26S proteasome is the large complex that
recognizes poly-ubiquitinated proteins and breaks them down into short peptides. At the
core of the complex is the 20S proteasome, comprised of seven α and seven β subunits
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arranged into four stacked rings. Three subunits (β1, β2, and β5) of the two inner β-rings
have catalytically active threonine residues at their N termini that perform the proteolysis.
The β2 subunit provides trypsin-like activity to cleave peptide bonds at the C-terminal
side of basic amino acid residues and is encoded by PSMB7 (Tanaka. 2009).
The β2 subunit is synthesized as an inactive precursor with an N-terminal
propeptide. The predicted full-length canine PSMB7 protein includes a 43 amino acid
propeptide that is removed in an autocatalytic reaction to yield a mature peptide of 235
amino acids. The mature peptide sequence of human PSMB7 is well-conserved with the
yeast homologue, PUP1 (Tanaka. 2009); human and canine sequences show 97% identity.
The c.146T>G mutation causes a glycine to be substituted for a valine, thus replacing a
large hydrophobic side chain with hydrogen. The valine is the sixth residue of the mature
peptide and is highly conserved (Fig. B-3), although substitution with isoleucine, which
also has a large hydrophobic side chain, has been observed in several non-mammalian
organisms, including Drosophila melanogaster (Smyth and Belote. 1999).
β2 is the first subunit incorporated during β-ring assembly (Tanaka. 2009). Both
the N-terminal propeptide and C-terminal extension of the β2 subunit are necessary for
proper proteasome assembly; in human cells, deletion of either domain is lethal (Ando et
al. 2009; Arendt and Hochstrasser. 1999; Jager et al. 1999; Ravid and Hochstrasser. 2008). In D.

melanogaster, a missense mutation at residue 170 of PSMB7 causes early larval lethality
in homozygotes (Smyth and Belote. 1999). Heterozygotes exhibit a temperature-sensitive
phenotype, with no visible phenotypic effect when kept at 25°C but significant
developmental defects at 29°C (Smyth and Belote. 1999). The authors propose that the
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PSMB7 mutation has a dominant negative effect and disrupts the function of the entire
proteasome (Smyth and Belote. 1999)). Additionally, in vertebrate cells, it was shown that
disruption of the β2 subunit causes an accumulation of poly-ubiquitinated proteins in
vivo. This provides further evidence supporting a critical role for maintaining integrity of
the proteasome (Tanahashi-Hori et al. 2003) .

Figure B-3. Protein sequence alignment of PSMB7/PUP1. The missense mutation in harlequin
dogs occurs at the sixth position of the mature peptide, indicated by the arrow. Amino acid
conservation between several species is shown below the PSMB7 sequence. Conservation
between PSMB7 sequences and the yeast homologue, PUP1, is shown below the PUP1 sequence.
Asterisks indicate identical residues while colons and periods denote conservative and semiconservative substitutions, respectively.

To our knowledge, harlequin is the first naturally occurring phenotype attributed
to mutation of the β2 subunit. Because HH is not viable and because studies have shown
that loss of trypsin-activity per se is not lethal (Arendt and Hochstrasser. 1997; Heinemeyer
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et al. 1997), we hypothesize that the p.Val49Gly variant causes a dominant-negative effect

by compromising the assembly and/or function of the proteasome complex. Each 20S
proteasome contains two β2 subunits; 75% of proteasomes in an Hh dog will presumably
have one or two mutant components. The absence of a detectable phenotype in mmHh
dogs suggests that the harlequin pattern of MmHh dogs results from an interaction
between mutant SILV and the impaired proteasome. Direct interaction of SILV and the
proteasome has been previously reported (Vigneron et al. 2004).
The M allele of SILV yields mutant transcripts with large insertions (Clark et al.
2008), presumably resulting in aberrant proteins targeted for degradation. The dilute

background of merle dogs (Mmhh) is the result of haploinsufficiency: a single wild-type
allele is insufficient for normal pigmentation. Additional studies are necessary to
determine how, in the presence of mutant SILV, the H allele of PSMB7 interferes with
the function of wild-type SILV to cause the amelanic background of harlequin dogs
(MmHh). One possible explanation is that proteasome function is impaired and unable to
meet the increased demand for proteasome activity created by accumulating defective
SILV. Mutant SILV may then reach toxic levels and cause death of melanocytes, or could
exert a dominant-negative effect by creating a multimer with wild-type SILV, preventing
the formation of a functional fibril matrix.
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Appendix C
Exclusion of COL2α1 in canine Legg-Calvé-Perthes Disease*

Source/description: Legg-Calvé-Perthes Disease (LCPD) is a developmental disease
characterized by osteonecrosis of the coxofemoral joint in young dogs (<18 months)
(Demko and McLaughlin. 2005). LCPD most commonly occurs in breeds of small stature,

i.e., toy, miniature, and terrier breeds. Radiographic evidence of lucency in the femoral
head and articular incongruency are hallmarks used for diagnosis of LCPD; the etiology
is currently unknown. LCPD most commonly occurs in breeds of small stature, i.e., toy,
miniature, and terrier breeds. The West Highland White Terrier (WHWT) is one of 11
breeds with increased risk for development of LCPD (LaFond et al. 2002).
Canine LCPD is clinically and pathologically similar to LCPD in humans (Roperto et al.
1992). Two independent studies of LCPD in human families reported a mutation in

COL2A1 which segregates with the disease (Miyamoto et al. 2007; Su et al. 2008).
Therefore, COL2A1 was investigated as a candidate gene for canine LCPD.
Study design: Genomic DNA was extracted from whole blood of 38 WHWTs. Of these,
15 were diagnosed with LCPD by veterinarians. Sequencing primers were designed
(Table S1), and PCR was performed following the manufacturer recommendations for
ThermoPrime Master Mix with ReddyMix (ABgene). DNA sequences for the 54 coding
exons and intron-exon junctions were determined by direct sequencing. Sequences were
*Reprinted with permission from “Exclusion of COL2α1 in canine Legg-Calvé-Perthes
Disease” by A.N. Starr-Moss, K.L. Nowend, K.M. Alling, E.J. Zepp and K. Murphy,
2012. Animal Genetics, 43, 112-113, Copyright 2012 by John Wiley & Sons, Inc.
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assembled for two WHWT: one LCPD-affected and one control. Polymorphisms among
the two dogs and the CanFam2 reference sequence were examined in four to ten
additional WHWTs in order to evaluate potential associations. Thirty-eight SNPs from
the Affymetrix version 2 custom canine SNP array surrounding the COL2A1 locus on
chromosome 27 were selected for analysis. DNA preparation and genotype calls were
completed following the manufacturer’s Mapping 500K Assay protocol
(http://www.affymetrix.com/support/downloads/manuals/500k_assay_manual.pdf). The
whole-genome association analysis program PLINK (Purcell et al. 2007) was used to
analyze genotypes for association with LCPD
Analysis: Sequencing of COL2A1 revealed 18 SNPs and indels, but none segregated with
the affected dogs. Additionally, SNPs across a 1.9 Mb region including COL2A1 were
not in linkage disequilibrium with LCPD (Table S2). We expected to see a co-segregation
of SNPs with disease if COL2A1exerted a major effect. A regulatory mutation is unlikely.
This study suggests that a mutation of COL2A1 is not responsible for LCPD in WHWT.
Acknowledgements: Owners of WHWT are thanked for providing samples. This work
was supported by the Westie Foundation of America, Inc. and the AKC Canine Health
Foundation. The authors additionally wish to thank the Clemson University Genomics
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